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INTRODUCTION 
                         Abdominal surgery is inevitably followed by an episode of 
gastrointestinal hypomotility. Post Operative Ileus (POI) is defined as functional 
inhibition of propulsive bowel activity, irrespective of the pathogenic 
mechanism. POI often results in prolonged hospital stay and increased 
healthcare costs. 
                          
                         Ileus occurs from hypomotility of the gastrointestinal tract in the 
absence of mechanical bowel obstruction. The etiology of POI involves an 
inflammatory response to bowel manipulation. Opening the peritoneal cavity 
and subsequent handling of the intestines during abdominal surgery triggers a 
neurogenic response,leading to local inflammation of the intestinal muscular 
layer and influx of leucocytes. This, together with systemic inflammatory 
response to surgery, are pivotal in the pathophysiology of POI following 
abdominal surgery. 
 
                         Other factors believed to contribute to POI are anaesthetic 
agents, perioperative narcotics and postoperative sympathetic overactivity 
(Livingston and Passaro,1990).Common symptoms associated with POI 
includes abdominal distension, nausea,vomiting,not passing stools and inability 
                   
to tolerate solid diet. Delay in starting oral diet inturn results in 
catabolism,hypoalbuminemia and poor wound healing. POI may also affect the 
patient’s mobilisation further resulting in pulmonary complications. 
 
                          Some of the typical preventive and treatment modalities are 
Nasogastric intubation,mobilisation,administration of laxatives and prokinetic 
agents.Although some studies have shown early return of bowel function when 
a combination of these interventions are used, individual strategies do seem to 
have an effect.Experimental studies have shown that stimulation of the vagus 
nerve after abdominal surgery, by electrical or pharmacological means, 
attenuates the inflammatory response and aids in the early return of bowel 
function. Thus gum chewing in the postoperative period aids in the early return 
of bowel function through cephalic vagal activation. 
 
 
 
 
 
 
                   
REVIEW OF LITERATURE 
INTRODUCTION: 
DEFINITION: 
                                      Post operative paralytic ileus is generally defined as a 
transient impairement of bowel motility after abdominal surgery, clinically 
characterized by bowel distention, lack of bowel sound and lack of passage of 
flatus and stool. In postoperative ileus, inhibition or small bowel motility is 
transient, and the stomach recovers within 24 to 48 hours, whereas colonic 
function takes 48 to 72 hours to return. Not all segments in the gastro intestinal 
tract are equally affected by postoperative paralytic ileus. The average paralytic 
state lasts between 24 to 72 hours. Twenty four hours in the small intestine, 24 
to 34 hours in the stomach and between 48 to 72 hours iin the colon after major 
abdominal surgery.So the effective duration of paralytic ileus is determined 
mainly by the return of colonic motility and in particular motility of the left 
colon. 
 
                                     Postoperative ileus also generates a significant burden to 
healthcare cost. Two large prospective cohort studies in the USA and the UK 
have demonstrated that gastrointestinal dysfunction is the most common type of 
postoperative complication after major non-cardiac surgery. In a retrospective 
                   
cohort study of patient records from >500 hospitals in the USA, ileus was found 
to be an important predictor of extended postoperative hospital stays and costs 
in patients undergoing colectomy. The economic burden of postoperative ileus 
has been estimated to exceed US $750 million per year and, interestingly, 
postoperative ileus was as expensive as managing severe postoperative 
complications (e.g. deep venous thrombosis, pulmonary embolism, surgical site 
infection) that might not lead to ileus.4 The possible benefits of improved and 
effective management of postoperative ileus include reduced use of resources, 
fewer complications and shortened hospital stay. 
 
Mechanisms of postoperative ileus: 
 
Postoperative ileus is immune-mediated: 
 
Since the beginning of the 20th century, postoperative ileus has been 
recognized as a highly prevalent consequence of abdominal surgery and the 
inhibition of gastrointestinal motility induced immediately after surgery was 
shown to primarily result from anaesthetics and opioid analgesics. Moreover, 
handling of the intestine during surgery activates inhibitory neuronal reflexes 
involving adrenergic and non-adrenergic pathways8, 9 and leads to intestinal 
oedema by excessive intravascular fluid loading.10 These events, however, fail 
to explain the prolonged inhibition of gastrointestinal motility seen during 
                   
several days after abdominal surgery. At the end of the 20th century, the 
inflammatory-mediated ileus hypothesis was introduced, derived from data 
illustrating that inflammation of the intestinal muscularis externa is the main 
mechanism underlying postoperative ileus.11 Handling of the intestine during 
abdominal surgery activates resident innate immune cells located within the 
muscularis externa, triggering the release of inflammatory cytokines and 
chemokines, as well as increased expression of adhesion molecules on 
endothelial cells, which causes circulating leukocytes (mainly neutrophils and 
monocytes) to invade the muscularis externa.11 Invading monocytes and 
activated resident macrophages produce nitric oxide and prostaglandins, 
compromising the contractile activity.12 This inflammatory response has also 
been confirmed in human intestinal surgical samples,13, 14 and is now considered 
to mediate impaired contraction of handled and inflamed tissue.15 Postoperative 
ileus, however, is not restricted to the small intestine but involves the entire 
gastrointestinal tract.16 The mechanisms underlying the generalized inhibition of 
gastrointestinal motility in response to this local inflammation comprise a 
complex neuronal and immunological response involving leukocytic production 
of nitric oxide,12 panintestinal dissemination of inflammation mediated by T 
helper (TH) cells, and activation of inhibitory neural pathways that affect the 
entire gut.17 
 
 
                   
 
 
 
 
 
Figure 1 | Postoperative ileus caused by local surgical manipulation induces the 
influx of leukocytes into the intestinal muscularis. This inflammatory response 
activates visceral sensory afferents and brainstem nuclei such as the nucleus of 
the solitary tract (NTS). We hypothesized that Intense manipulation triggers 
tissue damage and release of systemic inflammatory mediators that activate the 
area postrema (AP) in the brainstem. 
 
 
 
 
                   
                                                                                                                               
Innate and adaptive inflammatory mediators 
 
Although the influx of neutrophils and monocytes into the muscularis 
externa of the small bowel has been shown to underlie impaired gut motility 
after intestinal manipulation, the initial trigger of the inflammatory cascade is 
unclear and could involve dendritic cells, mast cells and/or macrophages.12, 18 In 
mouse studies, peritoneal mast cells were activated, which caused a subsequent 
release of mast cell mediators and an inflammatory response in the intestine.17 
In humans, intestinal manipulation during abdominal hysterectomy caused an 
immediate release of mastcell activation marker tryptase in the peritoneal fluid 
followed by an increase of proinflammatory cytokines IL-6 and IL-8. Patients 
who underwent minimally invasive surgery had lower levels of mast cell 
activation compared with those who had intestinal contact during open surgery14 
indicating that the degree of intestinal handling correlated with the level of mast 
cell activation and the subsequent inflammatory response. Moreover, mast-cell 
deficient KitW/KitWv mice failed to develop inflammation in the intestinal 
muscularis externa after surgery and reconstitution of mast cells in those mice 
restored the handling-induced inflammation in the intestine.18 
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MOUSE SMALL INTESTINAL MAST CELLS 
 
A- MUSCULARIS EXTERNA 
B- PEYER’S PATCH 
C- MESENTERY 
 
 
 
 
                   
                    An important feature of postoperative ileus is that it has a 
disseminated nature, whereby motility of the entire gastrointestinal tract is 
impaired even if only part of the intestine has been handled or is inflamed. 
Activation of inhibitory neural pathways by inflammatory mediators, such as 
cytokines and prostaglandins, has been proposed as the underlying 
mechanism.17, 19  An alternative theory is that the inflammatory response is 
disseminated by memory T cells to unmanipulated areas of the gastrointestinal 
tract, which could underlie the panenteric nature of postoperative ileus.20 
Intestinal manipulation could stimulate resident dendritic cells to release IL-12 
and trigger TH1 memory cells to egress into the systemic circulation and 
migrate to non-manipulated areas of the intestine. These TH1 memory cells 
release IFN-γ, which results in stimulation of macrophages in the muscularis 
externa and dissemination of the inflammatory response.44 
 
The vagal anti-inflammatory pathway 
During the past decade, the importance of the vagus nerve in regulation of 
intestinal immunity was established. In a rat model of sepsis,20 electrical 
stimulation of the vagus nerve was shown to reduce tumour necrosis factor 
(TNF) levels, indicating that inflammation had been decreased, and to improve 
survival. Neuronal acetylcholine receptor α7 signalling is involved with 
mediating the effects of vagus nerve stimulation.21 The anti-inflammatory effect 
of the vagus nerve is part of a reflex by which the brain senses inflammatory 
                   
information in the periphery through vagal afferents and subsequently creates an 
integrated anti-inflammatory response through vagal efferent fibres.22 Our 
research group showed in a mouse model of postoperative ileus that electrical 
stimulation of the vagus nerve reduces macrophage activation, dampens 
intestinal muscular inflammation and improves postoperative ileus.23 Moreover, 
immune cells in the intestinal wall are in close proximity to cholinergic nerve 
fibres further demonstrating that interaction between the nervous system and 
immune system is an important mechanism that modulates intestinal 
inflammation. The cholinergic neuronal circuitry can also be centrally 
stimulated pharmacologically by intracerebroventricular injection of 
semapimod (tetravalent guanyl-hydrazone known as CNI 1493) 24 or muscarinic 
agonist receptor (McN-A-343) 25 or by intravenous injection of a ghrelin agonist 
26 or acetylcholinesterase inhibitor (galantamine). 27 Moreover, the ‘cholinergic 
inflammatory reflex’ is also activated through enteral feeding of lipid-rich 
nutrition.28  These different interventions reduce manipulation-induced 
inflammation of the intestine and accelerate recovery of gastrointestinal motility 
in rodent models of postoperative ileus.24, 29  Interestingly, jatrorrhizine, an 
alkaloid isolated from medicinal plants, dose-dependently increased 
gastrointestinal transit in a rat model of ileus by activation of the cholinergic 
pathway.30 
 
 
                   
                            Our research group used a retrograde neuronal tracer, which 
travels along neurons and can be used to show neural connections from the 
periphery to the central nervous system, to show that intestinal inflammation 
triggers a vagus-nervemediated circuit leading to activation of vagal motor 
neurons in the brainstem that are connected to the inflamed intestine.31 These 
findings demonstrate that the anti-inflammatory pathway is indeed a hard-wired 
neural circuit. 
 
PHYSIOLOGY OF DIGESTIVE SYSTEM 
                                                         Digestion begins in the mouth, where the 
mechanical action of the teeth and tongue and the chemical action of saliva 
begin to break down food. 
 Saliva is produced by the salivary glands in the mouth. 
 It is composed primarily of water, mucus, various mineral electrolytes, and 
digestive enzymes including amylase, which begins the breakdown of food 
starches. 
 Saliva also serves to moisten and lubricate the mouth, provide minerals to 
maintain tooth enamel, and reduce the level of bacteria in the mouth.  
Upon being swallowed, food heads to the stomach, where it is bathed in gastric 
juice. 
                   
Gastric juice is a nearly colorless, strongly acidic liquid secreted by the gastric 
glands. 
 Its active food-dissolving ingredients are the digestive enzymes pepsin and 
rennin, which break down proteins, and hydrochloric acid.  
Gastric juice also contains mucus to protect the stomach lining from being 
dissolved by the acid. 
 
The half dissolved food then reaches duodenum (the first section of the small 
intestine), where it is acted upon by two digestive juices . 
  
First is the pancreatic juice secreted by the    pancreas which contains varied 
digestive enzymes like amylase, lipase and trypsin.  Trypsin breaks down 
protein; lypase  breaks down fats. Amylase,  as in the mouth, works by turning 
starch into sugar The second digestive juice released in the duodenum is bile, 
also known as gall, a yellow-green fluid produced by liver and stored in the gall 
bladder. Bile contains salts which emulsify the fats in the food so that they get 
absorbed by the linings of small intestine. 
                          Bile also serves to carry waste products from the liver                    
into the intestinal tract where they will eventually   pass  from  the body 
Unlike gastric juice, pancreatic juice and bile are both alkaline.               
                   
This helps to neutralize stomach acids as  the  food  moves  into  the  lower 
portions of the small intestine, where glands lining the walls secrete intestinal 
juice. 
 Also known as succus entericus, intestinal juice is a clear fluid containing a 
soup of enzymes.  It combines with pancreatic juice and bile to complete the 
digestion of proteins and fats. It  also helps in absorption of vital nutrients. 
The remaining nutrients are then absorbed into the intestine walls, and waste 
products pass to the large intestine to leave the body as feces. 
 
                   
 
      MAIN DIVISIONS OF THE DIGESTIVE SYSTEM 
 Alimentary Canal 
 Continuous, muscular digestive tube winding throughout the body 
 Digests and absorbs food particles 
 Contains the following organs: 
                     Mouth, Pharynx, Esophagus, Stomach, Small and Large Intestines 
 Accessory Digestive Organs 
 Contains the following organs: 
                     Teeth, Tongue, Gallbladder, Salivary Glands, Liver, and Pancreas 
                   
 
 
 
 
 
 
 
 
                   
 
                                            DIGESTIVE PROCESS 
  Ingestion 
 Mechanical digestion 
 Propulsion 
 Chemical digestion 
 Absorption 
 Defecation 
 
 
 
                   
 
                                           DIGESTIVE JUICES            
      The  digestive  juices  are  the  secretions  of  the  digestive  tract  that  break 
down  food.  They include saliva, gastric juice, pancreatic juice, bile, and 
intestinal juice.   The digestive juices are secreted by different organs, vary 
widely in chemical composition, and play different roles in the digestive 
process. Each is constantly produced by the body in small amounts, but the 
presence of food as it passes through the digestive tract causes increased 
production and secretion. 
         SALIVA- MAIN CONSTITUENTS AND THEIR FUNCTION 
 
                   
                        REGULATION OF SALIVARY SECRETION 
•   The secretion of saliva is controlled by both sympathetic and 
parasympathetic neurons. Both of them stimulate salivary secretion ,with 
the parasympathetic producing the greater response. 
•   There is no hormonal regulation of salivary secretion. 
• Both the facial nerve (CN VII) and glossopharyngeal nerve (CN IX) carry 
parasympathetic nerve fibers to the salivary glands. 
• Parasympathetic stimulation causes mostly watery, enzyme-rich secretion 
of the salivary glands. 
• The thought, sight, and/or smell of food stimulate the salivatory nuclei in 
the medulla to increase parasympathetic innervation to the salivary 
glands. 
• Acidic substances and the pressure of chewing also cause an increase in 
parasympathetic innervation to the salivary glands. 
• Nausea and intestinal irritation also stimulate salivation. 
• Fear, fatigue, sleep, and dehydration inhibit salivation. 
• Sympathetic stimulation of the salivary glands causes them to produce 
small amounts of viscous (mucus) saliva. 
 
                   
                                 GASTRIC JUICE CONSTITUENTS 
1) ORGANIC CONSTITUENTS 
                                        Pepsin (the proteolytic enzyme), mucin, intrinsic 
factor (a mucoprotein, necessary for absorption of vitamin B12 ) , gastric 
rennin (not present in human adults) , and other gastric enzyme  ( 
lysozyme ,carbonic anhydrase ,etc )  
2) NORGANIC CONSTITUENTS 
                                              Free hydrochloric acid, lactic acid and other 
fermenting acid, sulphates, chlorides, phosphates of sodium, potassium, 
calcium, magnesium, bicarbonates 
                                     GASTRIC JUICE FUNCTIONS 
• Pepsin converts proteins into simpler, more easily absorbed substances; it 
is aided in this by hydrochloric acid, which provides the acid environment 
in which pepsin is most effective.  
• Role of HCl  
           – Acid sterilization 
           – Activation of pepsinogen  
           – Promotion of secretin secretion 
                   
– Assisted effect of iron and calcium absorption . 
• Rennin aids the digestion of milk proteins. 
•  Mucus secreted by the gastric glands helps protect the stomach lining 
from the action of gastric juice  and aids in lubrication of the mucosal 
surface. 
•  Intrinsic factor is necessary for the absorption of vitamin B12  
                        THREE PHASES OF GASTRIC SECRETION 
 Cephalic Phase 
 Stimulated by the thought, sight, taste, or aroma or food 
 Inputs from olfactory receptors and taste buds travel to 
parasympathetic enteric ganglia which then stimulate 
stomach glands 
 Gastric Phase  
 Stomach distension activates stretch receptors 
 Food chemicals (e.g. peptides, rising pH) activate 
chemoreceptors which activate G cells which secrete gastrin 
 
 
                   
 Intestinal Phase 
 Presence of low pH and partially digested foods in 
duodenum stimulates intestinal gastrin secretion 
            
 
                         DIGESTIVE PROCESS IN THE STOMACH 
 
 
 
                   
 
                             GASTRIC MOTILITY AND EMPTYING 
 
 
 
 
 
 Peristaltic waves approach stomach and become stronger near pyloric 
region 
 Pyloric sphincter allows ~ 3 mL of chyme to pass to duodenum and the 
rest to return to stomach for further mixing 
 
                   
 
                                               PANCREATIC JUICE 
A) COMPOSITION 
•  Water 
• Proenzymes  
• Enzyme 
      •   Regulatory molecules 
• HCO3 
• Other electrolytes  
B) FUNCTIONS 
•                       The enzymes found in pancreatic juice break down all of 
the major nutrients, including carbohydrates, proteins and fats.  
•  Bicarbonate is useful in neutralizing the acidic gastric acid, allowing for 
effective enzymic action(ensuring pH Optimum)  
          PROTEIN COMPONENTS OF PANCREATIC JUICE 
 Inactive proenzymes  
– trypsinogen  
– chymotrypsinogen  
                   
– proelastase  
– procarboxipeptidase  
– prophospholipase  
 Active enzymes 
– α-amylase 
– ribonuclease  
– deoxyribonuclease  
– lipase 
– esterases  
  Regulatory molecules 
– colipase  
– trypsin-inhibitor 
– CCK-secretion regulating 
   Peptide 
 
 
 
                   
                
 
PHASES OF PANCREATIC SECRETION 
 The cephalic phase contributes approximately 25% to the pancreatic 
response,33 and is  vagally mediated. The stimulants are sight, smell, taste 
and eating of food.  
• The  vagal effect is mediated not only by acetylcholine but by other  
neurotransmitters like VIP and GRP.34 
 The gastric phase contributes 10% to the response, and is also via vagal 
innervation, mainly through stomach distention as it fills with food.  
 The  intestinal phase( 50 –- 75%),is mediated by secretin and 
cholecystokinin.36 
 
 
                   
 
 
 
                   
 
                       PHASES OF PANCREATIC SECRETION 
 
• The CCK released can activate vagal afferent neurons37 that carry the 
signal to the dorsal vagal complex where the sensory information is 
integrated and vagal efferents are activated.  
• Vagal efferents synapse with neurons in the pancreatic ganglia.  
• In turn, via the neurotransmitters, acetylcholine (Ach), gastrin-releasing 
peptide (GRP) and vasoactive intestinal polypeptide (VIP) effector 
neurons in the pancreatic ganglia activate secretion by pancreatic acinar 
cells.39 
                   
 
 
 
• In  addition to activating the neural pathway, CCK released by the I cell41 
enters the general circulation and may act as a hormone on the pancreatic 
acinar cells to cause secretion.  
• Pancreas produces a specific peptide known as pancreatic polypeptide 
(PP), which acts to negatively feedback42 on pancreatic secretion; that is, 
it inhibits enzyme secretion. PP is released in response to vagal nerve 
stimulation. 
 
                   
                CCK MEDIATED PANCREATIC SECRETION                    
 
 
 
                                           BILE CONSTITUENTS 
• Water (makes up 97% of bile) 
• Bile salts/acid (derivatives of cholesterol-  cholic acid, chenodeoxycholic 
acid) 
• Lecithin (increases solubility of cholesterol) 
• Cholesterol 
• Electrolytes (Na+, K+, Ca++,Cl-,HCO-3) 
• Inorganic salts –sodium bicarbonate 
• Bilirubin and biliverdin  
 
 
                   
 
                                      BILE FUNCTIONS 
• Bile aids in the emulsification of fats. 
•  Since bile increases the absorption of fats, it is an important part of the 
absorption of the fat-soluble substances, such as the vitamins A, D, E, and 
K. 
• It serves also as the route  of cholesterol and bile pigments bilirubin, a by-
product of red blood cells recycled by the liver. 
• Bile is alkaline and also has the function of neutralizing any excess 
stomach acid before it enters the duodenum. 
• Bile salts also act as bactericides, destroying many of the microbes that 
may be present in the food.  
 
 
 
                   
 
                  MECHANISMS PROMOTING THE SECRETION OF BILE 
 
• Acidic, fatty chyme enters duodenum and causes release of secretin and 
cholecystokinin (CCK)  from duodenum wall enteroendocrine cells. 43 
• CCK and secretin enter bloodstream. 
• Bile salts stimulate the secretion of bile from the liver (via the 
enterohepatic circulation). 
• Secretin stimulates biliary duct cells to secrete bicarbonate and water, 
which expands the volume of bile and increases its flow out into the 
intestine.  
• Vagal stimulation causes weak contractions of gallbladder.  
• CCK causes gallbladder to contract and hepatopancreatic sphincter to 
relax: bile enters duodenum.  
• Bile salts reabsorbed into blood. 
                   
                  INTESTINAL JUICE CONSTITUENTS AND FUNCTION  
• It contains 98.5% water and 1.5% solids. 
 Inorganic constituents 
• Sodium, potassium, calcium, magnesium with chloride,bicarbonate and 
phosphate. 
 Organic constituents 
• Enterokinase- activator of trypsinogen . 
• Erepsin  
• Nuclease,  nucleotidase , nucleosidase. 
• Arginase-acts on arginine producing urea and ornithine . 
• Amylase , sucrase, maltase, lactase, and isomaltase . 
 Also contain mucus which in combination with bicarbonates provides 
alkaline medium and prevents intestinal  mucosa from acid.               
REGULATION OF SECRETION 
 Secretion is regulated by both Nervous and Hormonal  mechanisms. 
 Nervous Regulation: 
• Stimulation of parasympathetic nerves  increases secretion while 
stimulation by sympathetic nerves decreases secretion. 
• However, the local nervous reflexes play an important role in increasing 
the secretion of intestinal juice: 
 
                   
 When  chyme enters the small intestine, the mucosa is stimulated by 
tactile stimuli or irritation,it causes the development of local nervous 
reflexes,which stimulate the glands of intestine. 
 Hormonal Regulation: 
• When  chyme enters the small intestine, intestinal mucosa secretes 
secretin and cholecystokinin that promote the secretion of intestinal juice. 
 
 
 
                   
REGULATION OF GASTROINTESTINAL MOTILITY 
INNERVATION OF THE GIT 
1)CENTRAL NERVOUS SYSTEM 
 
 
 
                       
 
 
 
                   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                   
AUTONOMIC NERVOUS SYSTEM AND GIT 
2) AUTONOMIC INNERVATION OF THE GIT 
 
 
 
 
 
                   
 
3) INTRINSIC (ENTERIC) NERVE PLEXUS 
 
Located    
in the submucosa (submucosal or Meissner’s plexus) and between 
circular and longitudinal muscle layers (myenteric or Auerbach’s plexus) 
Control 
          Motility - Myenteric plexus Excitatory  ‐    Acetylcholine,                 
Substance P,Inhibitory - VIP, nitric oxide 
 
Secretion - Submucosal plexus 
through release of neurotransmitters (excitatory – acetylcholine) 
 
                   
 
 The enteric nervous system coordinates  
digestion,  
secretion  
motility  
to optimize nutrient absorption.  
 Its activity is modified by information  from local chemical and 
mechanical sensors from the CNS 
 
                                   
                   
  GASTROINTESTINAL REFLEX 
 
                         GASTROINTESTINAL SMOOTH MUSCLE 
 All smooth muscle except: 
 Upper third oesophagus – striated 
 Middle third of oesophagus – mixed 
 External anal sphincter – striated 
 Areas of striated muscle are areas that are under conscious control 
 
 
                   
ANATOMICAL PROPERTIES OF GI SMOOTH MUSCLE: 
 
Form hollow tubes  not contracting against skeleton 
Form a syncitium - electrically coupled, joined by gap junctions  contractions 
synchronous  
Actin:myosin ratio 15:1 (skeletal muscle 2:1)  
Contractile elements not arranged in sarcomeres  not striated 
 
                   
GENERAL FUNCTIONAL CHARACTERISTICS: 
. Lower excitability, slower contraction and relaxation 
Higher extensibility 
Tonic contraction 
Auto rthymicity 
More sensitive to stretch, chemicals, cold and warm stimulation but not to 
electric stimulation 
ELECTRICAL ACTIVITY OF GI SMOOTH MUSCLE 
Resting potential 
Action potential 
Relationship to contraction 
 Slow wave or basic electric rhythm 
The smooth muscle membrane slowly depolarizes and repolarizes in a cyclic 
fashion  
                   
 
SLOW WAVES IN GI SMOOTH MUSCLE 
 Slow waves are changes in resting membrane potential  
 3-12 cycles per minute depending on area of GI tract - 3/min in stomach, 
12/min small intestine 
 Always present but do not always cause contractions  
 Frequency of contractions dictated by frequency of  slow waves 
 Slow wave frequency and height  modulated by –  
• body temp & metabolic activity,  
• intrinsic & extrinsic nerves 
• circulating hormones 
 
 
                   
RELATIONSHIP TO CONTRACTION 
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            ACTION POTENTIAL IN GI SMOOTH CELL 
 
                   
ELECTRICAL ACTIVITY AND SMOOTH MUSCLE 
CONTRACTION 
STIMULUS                                                      EFFECT ON MUSCLE 
1) Stretch of GI tract wall                      more depolarised smooth muscle     
            2. Acetylcholine release                      more excitable 
3. Parasympathetic stimulation          leads to action potential   
                                                               and muscle contraction 
4. Noradrenaline release                     More hyperpolarised muscle, so  
5. Sympathetic stimulation                  fewer contractions 
 
GI motility 
There are many types of contractions in different areas of the GI tract. 
Some muscles contract and relax in seconds – Phasic Contractions 
    -Peristalsis and Segmentation 44 
Some maintain contractions over minutes or hours – Tonic Contractions 
    -Sphincter 
 
                   
 
 
SYSTEMIC INFLAMMATION AND ENHANCED BRAIN 
ACTIVATION IN POSTOPERATIVE ILEUS 
 
                                      The severity of POI has been reported to result from 
decreased contractility of the muscularis inversely related to the number of 
infiltrating leukocytes. However, we previously observed that the severity of 
POI is independent of the number of infiltrating leukocytes, indicating that 
different mechanisms must be involved. Here, we hypothesize that the degree of 
tissue damage in response to intestinal handling determines the upregulation of 
local cytokine production and correlates with the severity of POI. 
 
Methods: Mice were subjected to gentle manipulation of the small intestine 
(gentle IM), more intense manipulation (intense IM), or only laparotomy. 
                   
Postoperative intestinal transit, local and systemic inflammatory response, I-
FABP (a marker for tissue damage) levels and brain activation were determined. 
Finally, in humans the duration of POI, plasma levels of I-FABP and 
inflammatory cytokines after open and laparoscopic segmental colectomy were 
measured. 
  
Results: Intense IM induced a more pronounced ileus compared to gentle IM 
(P=0.0001). No difference in leukocytic infiltrates in the handled and non-
handled 
parts of the gut was observed between the two IM procedures. However, intense 
IM resulted in significantly more severe tissue damage and was accompanied by 
a systemic inflammation with increased plasma levels of pro-inflammatory 
cytokines. In addition, intense but not gentle IM triggered enhanced c-Fos 
expression in the nucleus of the solitary tract and area postrema (P=0.0014). In 
patients, plasma levels of I-FABP and inflammatory cytokines were 
significantly higher after open compared to laparoscopic surgery, and were 
associated with more severe POI. 
 
Conclusions: Not the influx of leukocytes, but rather the manipulation-induced 
tissue damage and subsequent inflammatory response determine the severity of 
                   
POI. The release of tissue damage mediators and pro-inflammatory cytokines 
into the systemic circulation most likely contribute to the impaired motility of 
nonmanipulated intestine. 
 
                            Postoperative ileus (POI) is characterized by a transient 
inhibition of gastrointestinal (GI) motility following surgery. Patients 
experience significant discomfort such as abdominal distention, nausea and 
inability to pass stool or tolerate food. Especially prolonged ileus leads to an 
increased risk for wound dehiscence, pulmonary and thromboembolic 
complications and a prolonged hospital stay and is associated with an enormous 
economic burden.52  During the last decade, evidence has accumulated that 
intestinal inflammation evoked by handling of the intestine is a key mechanism 
underlying impaired GI motility following surgery,both in humans and in 
animal models. These studies demonstrated that infiltrating leukocytes inhibit 
the contractile activity of the manipulated intestine by local release of pro-
inflammatory mediators such as nitric oxide and prostaglandins.52,53 
 
 
                              It is becoming increasingly clear that POI mainly results 
from intestinal handling of the intestine during surgery.54 In rodents, Kalff et al. 
elegantly showed that manipulation of the intestine triggered the influx of 
leukocytes in the muscularis, starting from 3 hours onwards and further 
                   
increasing up to 24 hours after surgery. Of note, the number of infiltrating 
leukocytes increased with the severity of intestinal manipulation with 
compression of the intestine yielding more influx than running along the 
intestine with cotton swaps.55 These infiltrating leukocytes, mainly monocytes, 
subsequently release inflammatory mediators such 
as prostaglandins and nitric oxide impairing the contractility of smooth muscle 
strips of the intestine.56 The latter has been proposed to underlie the delay in 
intestinal transit observed 24 hours after the abdominal surgical procedure. 
 
 
                               Recently, however, we observed that eventration of the 
small intestine and graded manipulation of the intestine up to 3.5 grams did not 
delay GI transit, but was associated with influx of leukocytes to the same level 
as more intense manipulation that did lead to POI.57 These data would imply 
that other mechanisms must be involved. 
 
 
                                  Based on the above, we reasoned that the degree of tissue 
damage evoked by intestinal handling may be an important determinant of the 
severity of POI. Several clinical studies indeed have reported an increased 
postoperative inflammatory response related to increased operative trauma with 
systemic release of cytokines and systemic spread of the inflammatory 
                   
response.58,59  Tissue damage can trigger an innate immune response via the 
local release of damage-associated molecular pattern molecules,60 evoking an 
inflammatory response involving macrophages and/or mast cells. The resulting 
enhanced local inflammation may result in a more systemic inflammatory 
response with increased serum levels of pro-inflammatory  cytokines. The latter 
will consequently affect distant regions of the gut and contribute to the 
generalized aspect of POI. 
                               In the present study, therefore, we investigated the 
mechanism behind severe POI by studying the local and systemic inflammatory 
response, including brain stem activation after different intensities of intestinal 
handling. 
 
Laboratory animals were kept under environmentally controlled conditions 
(light on from 8:00 AM to 8:00 PM with water and food ad libitum; 20°C–
22°C, 55% humidity). Ten to twelve weeks old C57NL/BL6 mice were 
purchased from Charles River Laboratories (Maastricht, The Netherlands). Mice 
were maintained at the animal facility of the Academic Medical Centre in 
Amsterdam and were used at 12– 14 weeks of age. Studies were performed 
according to the guidelines of the Dutch Central Committee for Animal 
Experiments. All experiments were approved by the 
Animal Care and Use Committee of the University of Amsterdam (Amsterdam, 
The Netherlands 
                   
 
Patients undergoing elective segmental colectomy for colonic cancer were 
invited to participate. The protocol was approved by the Medical Ethics Review 
Board of the Academic Medical Center in Amsterdam (The Netherlands) and 
was conducted in accordance with the principles of the Declaration of Helsinki 
and good clinical practice guidelines. 
 
                                   Anaesthesia was performed by an intraperitoneal (i.p.) 
injection of a mixture of Ketamine (Ketalar 100 mg/kg) and Xylazine (Rompun 
10 mg/kg). Mice (5–8 per group) underwent a laparotomy alone, or a 
laparotomy followed by small intestinal manipulation (IM).61 Surgery was 
performed as follows: a midline abdominal incision was made and the 
peritoneum was opened over the linea alba and the small 
bowel was carefully layered on a sterile moist gauze pad. The small intestine 
was manipulated from the distal duodenum to the cecum and back for a total of 
three times. Contact with or stretch on stomach or colon was strictly avoided. 
Gentle standardized bowel manipulation (gentle IM) was constructed using a 
sterile moist cotton applicator attached to a device enabling the application of a 
constant pressure of 9 grams to the intestine. The more intense manipulation 
(intense IM) was performed by compression of the small bowel using moist 
cotton applicators such that the luminal content was moved abroad as 
previously described. 12 After the surgical procedure, the abdomen was closed 
                   
by a continuous 2-layer suture (Mersilene, 6-0 silk). After closure, mice were 
allowed to recover for 3 hours in a heated (32 °C) recovery cage. 
RESULTS: 
1) Gastrointestinal transit: 
Intense manipulation leads to a more pronounced delay of intestinal transit 
compared to Gentle manipulation with similar leukocytic infiltrate in the 
manipulated small intestine. 
 
 
2) Intense handling leads to enhanced inflammation in the manipulated 
intestine 
                   
3) Intense IM results in tissue damage with release of cytokines into the 
circulation 
4) Intense IM induced tissue damage is associated with area postrema 
activation 
 
                                               Inflammation of the intestinal muscularis is 
abundantly demonstrated to underlie POI. Here we demonstrated that not the 
number of infiltrating leukocytes, but that rather tissue damage and the release 
of inflammatory cytokines into the circulation are important factors determining 
the severity of POI. Concomitantly we found in humans that open abdominal 
surgery leads to more tissue damage and increased levels of circulating 
cytokines compared with minimally invasive laparoscopic surgery. Finally, 
increased tissue damage and plasma levels of  cytokines lead to activation of the 
area postrema and PVN, possible contributing to the	 development	 of	 more	
severe	POI.	Taken	together,	our	findings	indicate	that	
more	 severe	 upregulation	 of	 pro‐inflammatory	 cytokines,	 in	 response	 to	
increased	tissue	damage,	with	“leakage”	of	pro‐inflammatory	cytokines	into	
the	systemic	circulation	significantly	contribute	to	the	severity	of	POI.	
The	pathophysiology	of	POI	involves	recruitment	of	leukocytes	into	the	
intestine	impairing	smooth	muscle	contractility.62	Incremental	degrees	of	
manipulation	 of	 the	 small	 intestine	 cause	 a	 progressive	 increase	 in	
leukocyte	 infiltration.	 These	 infiltrating	 leukocytes	 subsequently	 release	
                   
inflammatory	mediators	such	as	prostaglandins	and	nitric	oxide	impairing	
the	contractility	of	smooth	muscle	strips	of	 the	muscularis	and	have	been	
proposed	to	underlie	the	delay	in	intestinal	transit.	Up	to	date,	there	is	still	
a	 scarcity	 of	 information	 on	 the	 influence	 of	 the	 severity	 and	 extent	 of	
surgery	 on	 the	 duration	 of	 POI.1	 Graber	 et al.	 subjected	 6	monkeys	 to	 3	
operations	varying	in	extent	and	site	of	dissection.	In	this	cross‐over	study	
the	duration	of	postoperative	dysmotility	was	independent	of	the	
extent,	and	site	of	the	operative	procedure.19	However,	years	later	Uemura	
et al. showed	 in	 rats	 that	 the	 magnitude	 of	 the	 abdominal	 incision	 does	
affect	 the	 duration of	 POI.20	 We	 previously	 demonstrated	 that	 only	
externalization	 of	 the	 intestine outside	 the	 abdominal	 cavity	 already	
induced	a	significant	influx	of	leukocytes without	resulting	in	POI.7	Also	in	
the	 present	 study,	 no	 significant	 difference	 in leukocyte	 recruitment	was	
observed	in	the	small	intestinal	muscularis	following intense	IM	compared	
to	gentle	IM.	As	we	failed	to	demonstrate	that	increased	influx 
of	leukocytes	is	associated	with	prolonged	POI,	other	mechanisms	seem	to	
determine	the	severity	of	POI.	
	
																																																								It	 is	reasonable	to	speculate	that	more	severe	
handling	of	 the	 intestine	will	 result	 in	more	 tissue	damage.	Veenhof	et al. 
recently	 demonstrated	 a	 significant	 increase	 in	 IL‐6	 in	 serum	 of	 patients	
                   
undergoing	 open	 rectal	 procedures	 compared	 to	 patients	 undergoing	 a	
laparoscopic	procedure.		In	line,	several	studies	have	reported	an	increased	
postoperative	 inflammatory	 response	 related	 to	 increased	 operative	
trauma.		Damaged	tissue	releases	pro‐inflammatory	mediators	(also	called	
pro‐inflammatory	damage‐associated	molecular	patterns,	or	DAMPs)	such	
as	heat	shock	proteins,	uric	acid,	HMGB‐1,	SAP130,	DNA	and	S100	proteins	
that	are	normally	intracellular.	Mast	cells	and	macrophages,	two	cell	types	
known	 to	 be	 involved in the pathogenesis of POI, may be activated by 
interaction with these DAMPs.10 In the present study, we indeed recorded 
higher levels of I-FABP, a marker for tissue damage, both in mice and patients 
undergoing more severe intestinal handling. Moreover, intense IM was 
associated with more pronounced upregulation of pro-inflammatory cytokines, 
associated with detection of these cytokines in the systemic circulation. Clearly, 
this increased inflammatory response in the handled intestine will impair 
smooth muscle function. A possible additional factor contributing to more 
severe ileus may result from the increased levels of plasma cytokines activating 
the hypothalamic-pituitary-adrenal axis. During tissue trauma, immune cells 
release the pro-inflammatory cytokines IL-1, IL-6 a nd T NFα into the general 
circulation. These cytokines result in enhanced activation of the hypothalamus 
triggering hypothalamic-pituitary-adrenal activity.15, 21-24 This results in an 
enhanced sympathetic inhibition of intestinal motility through stimulation of α2-
adrenergic receptors on monocytes leading to an increased release of nitric 
                   
oxide.25 Indeed, our preliminary brain histology data (unpublished) indicated 
enhanced activation of the hypothalamic PVN in the intense IM mice that still 
had detectable systemic IL-6 levels 24 hours after surgery. Finally, the more 
enhanced delay in transit might result from direct activation of residential 
macrophages by	 circulating cytokines, DAMPs and other tissue damage 
products, or even bacterial  products. These muscularis-resident macrophages 
can induce nitric oxide synthase thereby further contributing to the 
postoperative impairment of GI motility.6, 26	
                                        As POI is characterized by impaired motility of the 
entire GI tract, including areas that have not been manipulated, other factors 
than local inflammation should be involved. Previously, evidence has been 
reported that the local inflammation, mainly via prostaglandins, activates 
afferent nerves triggering inhibitory neural pathways affecting motility of 
distant non-inflamed areas.2, 6, 26-28 More recently, 
Engel et al. showed that IM evokes local IL-12 production and thereby triggers 
TH1 memory cells to egress into the systemic circulation and migrate to 
nonmanipulated areas of the intestine. There, these TH1 memory cells stimulate 
macrophages in the muscularis externa leading to dissemination of the 
inflammatory response.14 In previous experiments, however, we were unable to 
demonstrate increased levels of IL-12.29 Moreover, we showed that RAG1 -/- 
mice, devoid of T cells, developed POI to the same extent as wild type mice,30 
suggesting that other mechanisms must be involved. In the present study, we 
                   
observed that IM of the small intestine resulted in an influx of leukocytes into 
the colon, but the degree of influx was not related to impaired motility. Notably, 
colonic transit was only delayed after intense IM but not following gentle 
manipulation although the influx of leukocytes was comparable. Similarly, the 
upregulation of inflammatory cytokine levels after intestinal handling, both after 
intense and gentle IM, did not differ from laparotomy mice (data not shown), 
indicating that reduction in colonic motility does not result from disseminated 
inflammation. Based on the observation that delayed colonic transit is rather 
associated with increased systemic levels of pro-inflammatory cytokines, we 
speculate that impaired colonic motility rather results from the known inhibitory 
effects of pro-inflammatory cytokines on smooth muscle function. Pro-
inflammatory cytokines such as TNFα, IL-1β, KC and MCP-1 may affect 
directly enteric neural coordination of motility or intestinal muscle 
contractility.[15-18;19;15] In addition, we showed that increased plasma levels 
of inflammatory cytokines, only observed following intense IM, activate the 
area postrema	 and	 NTS.16,	 17	 This	 activation	 may	 subsequently	 trigger	
inhibitory	neural	motor	pathways	affecting	distant	regions	of	the	gut	with	
enhanced	sympathetic	inhibition	of	intestinal	motility,	and	thereby	further	
contribute	to	more	severe	POI.2,6,	26‐28,	31 
In	 conclusion,	 our	 findings	 indicate	 that	 more	 severe	 upregulation	 of	
proinflammatory	 cytokines,	 in	 response	 to	 increased	 tissue	 damage,	with	
“leakage”	 of	 pro‐inflammatory	 cytokines	 into	 the	 systemic	 circulation	
                   
significantly	 contribute	 to	 the	 severity	 of	 POI.	 Our	 observations	 indicate	
that	 identification	 of	 the	 host	 cell(s)	 that	 initiate	 release	 of	 inflammatory	
cytokines	 into	 the	circulation	may	aid	 in	 the	development	of	 strategies	 to	
selectively	block	this	response	and	reduce	the	severity	
of	 ileus.	 In	 addition,	 more	 insight	 into	 how	 tissue	 damage	 triggers	 the	
release	of	systemic	cytokines	may	also	lead	to	therapeutics	to	prevent	this	
response.	
	
ROLE	OF	MAST	CELLS	IN	POSTOPERATIVE	ILEUS	
	
                                                        Postoperative ileus (POI) is characterized by 
a transient cessation of intestinal motor activity following abdominal surgery, 
and as a result, patients suffer from complications and prolonged hospital stay. 
The costs related to POI have been estimated to amount 1.47 billion dollars 
annually in the USA, illustrating its large socioeconomical impact . Regarding 
the pathogenesis of POI, it has become evident from animal and human studies 
that postoperative intestinal hypomotility in POI is the result of an influx of 
leukocytes into the manipulated muscularis externa 3, 4. Neutrophil infiltrates 
have been shown to inhibit local contractile activity, i.e. via the release of nitric 
oxide (NO) 5-7, or general motility via the activation of sympathetic inhibitory 
neural reflexes . The importance of this inflammatory response in POI is 
                   
underscored for instance by the success of therapeutic strategies aimed at 
blocking neutrophil recruitment to ameliorate POI. However, the 
pathophysiological mechanisms behind the immune response to bowel 
manipulation remain to be clarified. In this respect, an important factor could be 
the reduced epithelial barrier function resulting from bowel handling that was 
previously observed in rodent models of POI 65,66. This would be in line with 
previous observations that bowel wall mechanical stretch   and manipulation  
augments inflammatory responses of bowel wall macrophage populations and 
local dys-contractility via TLR activation. 
                                            We have previously shown that mast cells are 
crucial players in the intestinal inflammation that mediates POI 13 and that mast 
cell stabilizers and histamine receptor antagonists are instrumental in reducing 
POI in animal models66 and human POI4, . Mast cells are implicated in barrier 
dysfunction in animal models of chronic stress , allergic inflammation  parasitic 
infection  and endoxemia 67. Thus, given the implication of mast cells in the 
pathogenesis of POI, and their potential to regulate intestinal barrier function, 
we assessed the role of mast cell- induced barrier dysfunction in the occurrence 
of POI by using two mast cell deficient mouse strains, KitW/W-v and KitWsh/ 
W-sh. Here, we show that IM during abdominal surgery is associated with 
intestinal barrier dysfunction and inflammation of the manipulated bowel 
muscularis externa. Our data indicate that both inflammation and barrier 
                   
dysfunction are mediated by mast cells and can be considered as factors 
contributing to POI pathogenesis. 
   
                                               The prolonged impairment of gastrointestinal 
motility after intestinal manipulation is a significant confounding factor in 
postoperative recovery. Rodent models and human studies have demonstrated 
that surgical inspection and manipulation of the bowel leads to the activation of 
antigen presenting cells that reside in the intestinal muscularis layer . The 
general paralysis of the entire GI tract - including the unmanipulated segments- 
is a commonly seen characteristic of POI. This clinically important aspect of 
POI involves the activation of an inhibitory neural reflex arch by local 
inflammatory infiltrates 8, and was recently also shown to involve the 
production of IFN-γ by CCR9+T-cells that are activated at the site of 
manipulation . We have shown previously that the activation of mast cells 
resulting from local manipulation of the bowel is a pivotal factor in the 
pathogenesis of POI and the inflammatory response to local manipulation . 
Hence, we questioned in the current study whether mast cell derived mediators 
contribute to POI either as local activators of dendritic cells recruited to the gut 
wall or via epithelial permeability changes. 
                                            We show here that intestinal manipulation induces 
barrier dysfunction via a mechanism that is crucially dependent on mast cells. In 
patients, barrier dysfunction frequently occurs during abdominal surgery and 
                   
has been associated with increased postoperative septic morbidity in surgical 
patients undergoing laparotomy . In addition to this model of POI , as well as in 
human ileus , mast cell activation has been associated with disturbed intestinal 
barrier function in ulcerative colitis  and several disease entities such as stress-
induced hypersensitivity of the bowel  and endotoxemia 
. In these models, the rapid release of serine proteases following triggering of 
mast cells, possibly via release of Corticotropin Releasing Factor (CRF), is 
responsible for an increase in epithelial permeability. Likewise, the nature of the 
mast cell mediators that affect barrier function in our model involves similar 
rapid mechanisms and mediator release. This mechanism may involve the 
activation of protease activated receptor-2 (PAR-2) that is expressed on 
epithelial cells 67, although most studies have focused on PAR-2 activation by 
protease activity in the lumen. 
 Our data are in line with earlier observations in patients and rodent 
models implicating a disturbed intestinal barrier function after intestinal surgery 
involving bowel handling . It has been shown that in POI, bacterial products 
may reach the intestinal muscularis after IM of the small bowel 38 and that 
antibiotic treatment decreases muscular inflammation after colon manipulation . 
The implications of this process for the pathogenesis of POI are incompletely 
understood, but irrespective thereof, the clinical impact of bacterial 
translocation during surgery is significant. A recent study which included 927 
patients over 13 years showed that bacterial translocation was associated with 
                   
increased postoperative septic morbidity in surgical patients undergoing 
laparotomy 68. 
 In this study, we assessed barrier integrity by measuring bacterial 
translocation to the MLN. Most likely this process reflects dendritic cell 39 (or 
CX3CR1 expressing macrophages 40)- mediated uptake of bacteria that are still 
viable once transported by dendritic cells to the MLN. Thus the bacterial 
translocation is dependent on a number of immunological processes including 
phagocytosis, killing and bacterial cultures in the MLN may not reflect merely 
epithelial integrity. Therefore we performed measurements of barrier function in 
the small intestine in Ussing chambers, reflecting the para- and transepithelial 
transport of the 40kD HRP, as well as in vivo measurement of real time changes 
in epithelial leakage to the vena mesenteria. Using this combination of methods 
we demonstrated that IM in our model of POI led to a mast cell dependent 
epithelial barrier dysfunction. This mechanism may explain the important role 
of mast cells in the pathogenesis of POI and validate mast cells as a bona fide 
drug target to shorten POI and improve postoperative recovery and barrier 
function. We performed our experiments in two strains of mast cell deficient 
mice, KitW/W-v, and KitW-sh/W-sh mice which both carry mutations in the 
Kit gene (White spotting (W) locus). C-kit is the receptor for Stem Cell Factor 
(SCF) and involved in regulation of hematopoiesis, proliferation and migration 
of primordial germ cells and melanoblasts during development. The KitW/W-v 
mice carry the W mutation, resulting in deletion of the transmembrane domain 
                   
of the c-kit protein as well as the dominant negative Wv mutation, a point 
mutation that affects c-kit kinase activity. On the other hand, the mast cell 
deficient Kit-w-sh/w-sh mice carry a mutation that reflects an inversion in the 
kitlocus spanning a 2.8 mb segment. Hence, the resulting phenotypes are 
different: Kitw-wv mice have phenotypic abnormalities including sterility, 
anemia, lack of interstitial cells of Cajal (ICC), and have defects in 
hematopoiesis that lead to an absence of intra epithelial Tcells, neutropenia, and 
poor mobilization of blood neutrophils . In contrast, Kit-wsh/ w-sh mice, 
bearing the W-sash (W(sh)) inversion mutation, have mast cell deficiency but 
are not anemic nor sterile. Adult Kit-w-sh/w-sh mice have been shown to have a 
profound deficiency in tissue mast cells but normal levels of major classes of 
other differentiated hematopoietic and lymphoid cells . 
    As the pathogenesis of POI is mediated by neutrophil influx, we 
reasoned that the protection after IM in our POI model in these KitW/W-v mice 
might not be selectively dependent on the lack of mast cells. Therefore, we also 
carried out our experiments in the KitW-sh/W-sh mice for two reasons: first, in 
contrast to the KitW/W-v, the KitW-sh/W-sh mice can be tested against 
C57BL/6 WT control mice. Second, KitW-sh/W-sh have normal neutrophil 
numbers, are fertile, contain normal number of intra epithelial lymphocytes 
(IELS), and are not anemic. The latter likely explains why the effects of IM 
induced neutrophilic extravasation and inflammatory response were much less 
pronounced in the KitW-sh/W-sh compared to the KitW/W-v. 
                   
Interstitial cells of Cajal (ICC) require intact ckit signaling for proper 
development and are defective in both ckit mutant mice, although ICC subsets 
have been shown to develop in KitW-sh/W-sh mice . Because KitW/W-v mice 
are hemizygous we assessed basic GI motility in KitW-sh/W-sh that are on a 
C57BL/6 background. Indeed we observed a disturbed 
motility and delayed transit under normal conditions compared to C57BL/6 
mice. But this difference did not reach significance so we decided to include 
KitW-sh/W-sh in our motility analyses. 
                                              The observation that the bacterial translocation in 
KitW/W-v was almost completely abolished in both affected KitW/W-v as well 
as its control Kit+/+ may reflect a defective representation of innate immune 
cells in the lamina propria in these mice, given the purported role of lamina 
propria APCs in bacterial sampling . In addition, we observed that inflammatory 
parameters, bacterial translocation, and permeability to HRP differed between 
the control groups: C57BL/6 and Kit+/+. This is probably due to differences in 
immune responses that generally exist between mouse strains: for example 
between Balb/c and C57BL/6 45. 
 In this study we found that luminal bacteria were involved in IM induced 
inflammation and ileus by treating mice with antibiotics, indicating that 
bacterial translocation contributes to the POI. It has been described that the 
immune response is induced soon after IM, for example ICAM-1 mRNA is 
expressed in the muscularis within 15 minutes of manipulation , while luminal 
                   
products start to appear in the muscularis externa externa 6h after intestinal 
manipulation 38, indicating that translocated bacterial antigens may not trigger 
muscularis immune responses, but may exacerbate immune responses, as shown 
by our data presented here. It is important to note that lamina propria intestinal 
macrophages that form the first line of defense generally do not produce high 
levels of cytokines upon bacterial challenge. Rather, dendritic cells in draining 
lymph are activated by luminal antigens which may not lead to mucosal 
inflammation but can contribute to the pathogenesis of POI in unmanipulated 
areas . 
    We show in this study that IM is associated with a postoperative decrease in 
MAP. Hypoperfusion of intestinal tissue following abdominal as well as non-
abdominal surgery has been associated with impaired barrier function preceded 
by hypotension, mesentery hypoperfusion and enterocyte damage 70. In addition, 
these studies show that aberrations in actin reorganization, cell proliferation and 
mitochondrial function are maximal at 60 min. after mechanical bowel 
manipulation (i.e. the same time point at which we measured intestinal barrier 
function in the current study) and was partially recovered after 24 hours  (at 
which we measured inflammatory mediators). Although MAP decreases after 
IM, when MAP was pharmacological lowered, the intestinal barrier function 
was not affected and inflammation did not occur to a similar extend. Circulating 
SNP-derived NO causes smooth muscle relaxation and subsequent 
microvascular vasodilatation. NO might affect inflammatory processes and 
                   
intestinal barrier  function independent of blood pressure alterations but we 
show that NO has no effect on these processes. Of note, MAP measured in the 
carotid artery in our study likely reflects the blood pressure of the internal 
organs, but we cannot exclude that perfusion in the small intestine is different 
from the carotid artery. 
 Concluding, we show that IM elicits a mast cell dependent inflammatory 
response and intestinal barrier disturbances that may contribute to the 
pathogenesis of POI. Our study further underscores the potential of mast cell 
stabilization in ameliorating postoperative recovery, warranting that this 
treatment strategy should be pursued in clinical setting. 
 
From bench to bedside 
 Considerable progress has been made in understanding the mechanism 
behind postoperative ileus using experimental animals and several translational 
studies show that the pathophysiological mechanisms described above could be 
applicable to humans. However, it should be emphasized that data obtained in 
animal models might not necessarily translate to humans. For example, there are 
differences in mediators and receptor expression profiles between humans and 
rodents32; the presence of comorbidity, such as diabetes and hypertension is 
difficult to model in experimental animal studies; and the type of surgery 
studied. Moreover, there is a need for reliable outcome measures to evaluate 
clinical success in new drug trials. Parameters such as first defecation and flatus 
                   
are often used as primary outcome parameters in clinical trials; however, these 
parameters are rather unreliable. Time to first flatus strongly depends on patient 
reporting, and passage of stool might simply reflect rectal emptying and provide 
no reliable information on recovery of whole gut transit. Thus, with novel 
treatments for postoperative ileus in development, there will be a definite need 
for more reliable outcome parameters in order to evaluate new treatments.33 
 
Current postoperative ileus therapies 
Multimodal enhanced recovery programs 
As postoperative ileus is a multifactorial disorder, a multimodal approach to 
shorten the duration of disease has been advocated. Enhanced recovery after 
surgery (ERAS) protocols or fast-track programmes have been introduced in 
several surgical centres in order to accelerate recovery of gastrointestinal 
function, improve clinical outcome and reduce hospital length of stay.4 In these 
programmes,several perioperative measures including improved perioperative 
fluid management, early ambulation and feeding and optimal analgesia are 
incorporated into patient management to reduce the rate of perioperative 
morbidity.4, 34-37 
Laparoscopic surgery 
Minimal invasive surgery using laparoscopy has many potential advantages 
over conventional open surgery, including smaller incisions, reduced pain and 
inflammation, earlier gastrointestinal recovery and shorter hospital stay. Several 
                   
studies,38-43 and a 2012 meta-analysis that included 4614 patients with colon 
cancer,44 demonstrate that laparoscopic surgery significantly reduces time until 
recovery of bowel function (by 1 day on average) and duration of hospital stay 
compared with open colonic resections.45, 46 Furthermore, postoperative ileus 
occurs more frequently after conventional laparotomy than mini laparotomy for 
the resection of colorectal cancer.47 Therefore, minimally invasive surgery and 
fast-track perioperative care are likely to decrease the risk and/or duration of 
postoperative ileus. 
Prokinetics, local anaesthetics and laxatives 
A Cochrane review that evaluated the benefits of prokinetic agents including 
cisapride, erythromycin, cholecystokinin and dopamine antagonists indicated 
that routine administration of prokinetics for prevention of postoperative ileus is 
not recommended.48 The effectiveness of these agents is probably reduced as 
contraction of the inflamed gastrointestinal smooth muscle is strongly 
compromised by the inflammatory process. Metoclopramide is a dopamine D2 
receptor antagonist with mixed 5-HT3 receptor antagonistic and 5-HT4 receptor 
agonistic properties. It is commonly used to treat nausea and vomiting and to 
promote gastric emptying, especially in patients with diabetes mellitus and 
gastroparesis.49 These prokinetic characteristics of metoclopramide have led to 
evaluations of the drug as potential treatment of postoperative ileus. Clinical 
studies have reported conflicting results, with some demonstrating a reduction 
in time until first bowel movement and resumption of oral soft diet50 and some 
                   
showing no effect.51 Moreover, the number of patients included in these trials 
was low (only 16 per group), which makes it difficult to draw any solid 
conclusions and, therefore, further studies are required. 
Epidural local anaesthetics, for postoperative analgesia, used in conjunction 
with fast-track care minimize systemic opioid use and shorten the duration of 
postoperative ileus.4 Hence, epidural analgesia is included in most published 
ERAS protocols, and has been advocated in a recent published consensus 
review.37 
Laxatives such as bisacodyl or magnesium oxide are commonly used as part of 
a multimodal approach to manage postoperative ileus3 and preliminary studies 
have been positive. Laxatives are inexpensive treatments but further studies are 
required before general recommendations are made.34 
Alvimopan 
 Opioid agonists are often used for postoperative analgesia and, in 
combination with endogenously released opioids, contribute to postoperative 
ileus by decreasing intestinal motility through stimulation of μ-type opioid 
receptors in the gut.52 Alvimopan is a peripherally-acting μ-opioid-receptor-
antagonist. It belongs to a new class of drugs designed to reverse opioid-
induced gastrointestinal effects without affecting the centrally-mediated 
analgesic effects of opioids and, therefore, not compromise pain relief.53    
 A pooled, post-hoc analysis of four randomized, double-blind, placebo-
controlled, phase III trials54-57 showed that alvimopan led to a reduction in the 
                   
time until tolerance of solid food and bowel movement and a statistically 
significant reduction in the duration of hospital stay58. 
Hence, FDA approval was granted in 2008. However, the use of alvimopan was 
recently associated with an increased rate of myocardial infarction, limiting its 
clinical application.48, 53 Only one phase III trial was conducted outside North 
America and assessed the effect of alvimopan on postoperative bowel recovery 
after open abdominal surgery carried out at 70 hospitals in 11 countries, 
predominantly within the European Union.59 The study showed a potential 
benefit although it was not statistically significant, possibly as the opioid doses 
used in this trial were low.45,59 The drug was cost saving, although this has not 
yet been thoroughly assessed for treating patients undergoing laparoscopic 
surgery, but randomized, double-blind, controlled trials are currently running in 
the USA,60 to determine its therapeutic and cost saving potential in patients 
undergoing laparoscopic colonic resection.61 
Therapies currently in clinical trials 
1) Methylnaltrexone 
2) Lidocaine 
3) 5HT 4 receptor agonists 
4) Ghrelin agonists 
5) COX 2 inhibitors 
6) Gum chewing 
7) Mast cell stabilizers 
8) Blocking adhesion molecules and integrins 
 
                   
Other potential new therapeutic strategies: 
 Glycine has immunomodulatory effects in transplantation and sepsis, 
inhibiting the inflammatory reaction of macrophages and neutrophils by binding to 
specific glycine-gated chloride channels, subsequently modulating intracellular 
calcium concentrations. Glycine-gated chloride channels are localized to muscularis 
externa macrophages and infiltrating leukocytes. Moreover, in a rodent model of 
postoperative ileus, preoperative glycine treatment statistically significantly 
attenuated the inflammatory response and improved postoperative gastrointestinal 
transit. Thus, therapeutic modulation of resident macrophages by glycine could be a 
novel pharmacological strategy. 
Matrix metalloproteinase (MMP)-9, a member of the gelatinase family of 
MMPs, is upregulated following intestinal manipulation that leads to leukocyte 
migration into the intestinal muscularis externa. Inhibition of MMP-9 reduces the 
number of infiltrating inflammatory cells and prevents the surgically-induced 
reduction in contraction of bowel smooth muscle mice. Depleting DCs, the use of 
immunosuppressants such as anti-IL-12 antibodies or inhibiting Th1 cell migration 
by FTY-720 could reduce postoperative ileus, although these approaches should be 
used with caution because of the risk of increasing the risk of infection.44, 47 
 
 
                                  
              
 
                   
AIM OF THE STUDY 
 
          To evaluate the effect of chewing the chewing gum on the early 
return of bowel function postoperatively in patients undergoing 
laparotomy. 
OBJECTIVES: 
To study the effect of chewing the chewing gum in the postoperative 
period 
1)  on the early return of bowel function in patients undergoing 
laparotomy 
Bowel function assessed by: 
a) Post operative day of return of bowel sounds 
b) Post operative day of passage of flatus 
c) Post operative day of passage of faeces 
2) On the post operative day of start of oral feeds 
3) On the length of the hospital stay 
4) On the rates of postoperative anastamotic leak and abdominal wall 
dehiscense.  
                   
INCLUSION CRITERIA: 
1) Age more than 18 years 
2) Any sex 
3) All the patients undergoing elective/emergency laparotomy for 
gastrointestinal surgeries 
4) Patients consented for inclusion in the study 
 
EXCLUSION CRITERIA: 
1) Age less than 18 years 
2) Patients with past history of habitual constipation or inflammatory 
bowel disease 
3) Patients with previous history of laparotomy 
4) Patients on opioid or anticholinergic medication 
5) Patients on mechanical ventilation postoperatively for prolonged 
periods of time more than 6 hours or whose general condition is 
poor 
6) Edentulous patients 
7) Patients not consented for inclusion in the study 
 
 
 
 
                   
MATERIALS AND METHODS: 
Type of study:   prospective, randomised, control study 
100 patients included in this study were divided into two cohorts as follows: 
1) Study group – 50 
2) Control group – 50 
 
Protocol  for intervention in the study group: 
 Each of the fifty patient in the study group received about 9 pieces of  
commercially available sugarless chewing gum ( wrigley’s orbit, spearmint 
flavour) per day. Patients were advised to chew gum from about 6 hours post 
surgery. They were advised to chew gum in three sessions per day ,so 3 pieces 
of chewing gum per session in the morning, noon and night. All the patients in 
the study group were advised to chew gum till the start of the oral feeds. 
 
Protocol for the patients in the control group: 
 Routine management by nil per oral, intravenous fluids, antibiotics  and 
frequent clinical monitoring for the return of bowel sounds and the passage of 
flatus. 
 Oral feeds were started once the patient is deemed clinically fit for feeds. 
Patients in this group did not receive chewing gum. 
  
 
                   
Clinical parameters monitored in the postoperative period: 
   
1) Post operative day of return of bowel sounds 
2) Post operative day of first passage of flatus 
3) Post operative day of first passage of faeces 
4) Post operative day of start of oral feeds 
5) Post operative complications: 
a) Anastamotic leak 
b) Abdominal wall dehiscence 
6) Length of the hospital stay 
Relevant clinical parameters were checked for 3 times per day. 
No oral , intravenous, or rectal agents to stimulate the bowel motility were 
given. 
Statistical tools: 
 The information collected regarding all the selected cases were recorded 
in a Master Chart. Data analysis was done with the help of computer using 
SPSS 16 and Sigma Stat 3.5 version. 
Using this software range, frequencies, percentages, means, standard deviations, 
chi square and ‘p’ values were calculated by One way ANOVA and ‘t’ test. 
Kruskul Wallis Chi square test was used to test the significance of difference 
between quantitative variables. 
A ‘p’ value of less than 0.05 is taken to denote significant relationship. 
                   
Composition of chewing gum: 
1) Polyols – sorbitol, maltitol (sugar free sweetener) 
2) Gum base – soyabean lecithin 
3) Humectant glycerine (to preserve moisture) 
4) Sweetener aspartame E951(artificial non saccharide sweetener) 
5) Glazing agent – carnauba wax (to provide waxy homogenous coat to 
prevent water loss) 
6) Colouring agent E171 titanium dioxide 
7) Anti oxidant BHA (butylated hydroxyl anisole) 
 
 
           
      
 
                   
Results 
 The results of analysis of comparing the  patients who chewed chewing 
gum in the postoperative period(cases) and the patients who did not chew gum 
in the postoperative period(controls) are as follows: 
Table 1: 
  Age  cases  controls 
  <30  5  4 
  31‐40  9  7 
  41‐50  17  11 
  51‐60  13  18 
  >60  6  10 
  Total  50  50 
  Mean  46.82  51.06 
  SD  12.39  12.85 
  p value  0.096 Not significant 
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The mean age of the patients in the study group was 46.82 yrs and that of the 
control group was 51.06 yrs. The difference in the age group is not statistically 
significant as the p value is 0.096. 
 
 
 
 
                   
Table 2 
  Sex  Group 1  Group 2 
  MALE   34(68%)  34(68%) 
  FEMALE  16(32%)  16(32%) 
  Total  50(100%)  50(100%) 
  p value  0.875 Not significant 
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The total number of patients was 100(study – 50 and control – 50) 
Among them the male and female distribution was 34(68%) and 16(32%) in the 
study group and 34(68%) and 16(32%) in the control group respectively. The 
difference in the sex distribution is not statistically significant as the p value is 
0.875. 
                   
 
Table 3: 
diagnosis   Group 1  Group 2 
Acute intestinal obstruction   10(20%)  10(20%) 
Perforative peritonitis   22(44%)  23(46%) 
Blunt injury abdomen   3(6%)  3(6%) 
gastrointestinal malignancy  5(10%)  6(12%) 
Chronic duodenal ulcer with GOO   2(4%)  4(8%) 
intraabdominal abscess  3(6%)  1(2%) 
Hemoperitoneum‐umbilical vein rupture   1(2%)  0 
Stab injury abdomen   4(8%)  3(6%) 
Total  50(100%)  50(100%) 
 
The total number of patients diagnosed with acute intestinal obstruction was 10 
(20%) each in the study and the control group. The total number perforative 
peritonitis patients were 22 and 23 in study and control group respectively. The 
total number of patients diagnosed with blunt injury abdomen were 3 in each of 
the study and the control group. Number of patients with stab injury abdomen 
taken up for laparotomy were 4 and 3 in the study and control group 
respectively. Number of patients with gastrointestinal malignancy taken up for 
laparotomy were 5 and 6 in the study and control group respectively. 
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Table 4: 
     
procedure   Cases   Controls  
resection + anastamosis  14(28%)  14(28%) 
gastrectomy+gastrojejunostomy  6(12%)  9(18%) 
Exploratory laparotomy and appendicectomy   4(8%)  2(4%) 
primary closure of gastric and intestinal perforation  7(14%)  8(16%) 
Omenatal  patch closure   11(22%)  13(26%) 
                                other procedures  8(16%)   4(8%) 
 
PROCEDURE COMPARISON
14
6
4
7
11
8
14
9
2
8
13
4
0
2
4
6
8
10
12
14
16
res
ec
tio
n +
 an
as
tam
os
is
ga
str
ec
tom
y+
ga
str
oje
jun
os
tom
y
Ex
plo
rat
ory
 la
pa
rot
om
y a
nd
ap
pe
nd
ice
cto
my
 
pri
ma
ry 
clo
su
re 
of 
ga
str
ic 
an
d
int
es
tin
al 
pe
rfo
rat
ion
Om
en
ata
l  p
atc
h c
los
ure
 
oth
er 
pro
ce
du
res
CASES CONTROLS  
The total number of resection & anastamosis performed were 14 in each of the 
study and the control group. Number of primary closure of perforation done was 
7 in the study group and 8 in the control group. Total number of omental patch 
closures done were 11 and 13 in the study and control group respectively. 
Total number of gastrectomy & gastrojejunostomy done were 6 and 9 in the 
study and control group respectively. 
                   
Table 5: 
POD of return of bowel   Cases   Controls  
<4  43(86%0  17(34%) 
>4  7(14%)  33(66%) 
Total  50(100%)  50(100%) 
P VALUE  0.012  Sig 
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The total number of patients in whom there was early return of bowel 
sounds(within 4 days) was 43(86%)  in the study  group and 17(34%) in the 
control group respectively. The total number of patients in whom the  post 
operative return of bowel sounds was late( more than 4 days) was 7(14%) and 
33(66%) in the study and control group respectively. This is statistically 
significant as the p value is 0.012. 
                   
Table 6: 
 
POD of first passage of flatus  
Cases   Controls  
  <4  48(96%)  1(2%) 
  >4  2(4%)  49(98%) 
  Total  50(100%)  50(100%) 
  P VALUE  < 0.001   Sig 
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The total number of patients who passed flatus within 4 postoperative days was 
48 in the study group and 1 in the control group. The number of patients who 
passed flatus after day 4 was 2 and 49 in the study and control group 
respectively. This is statistically significant as the p value is <0.001. 
 
                   
 
Table 7: 
  POD of first passage of faeces   Cases   Controls  
  <6  48(96%)  2(4%) 
  >6  2(4%)  48(96%) 
  Total  50  50 
  P VALUE  < 0.001   Sig 
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The total number of patients who passed faeces within 6th post operative day 
was 48 in the study group and 2 in the control group. And the number of 
patients who passed faeces after the 6th POD was 2 and 48 in the study and the 
control group respectively. This is statistically significant as the p value is 
<0.001. 
                   
Table 8: 
  POD of starting of oral feeds   Cases   Controls  
  <4  46(92%)  8(16%) 
  >4  4(8%)  42(84%) 
  Total  50(100%)  50(100%) 
  P VALUE  < 0.001   Sig 
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The total number of patients in the study group for whom  the oral feeds were 
started earlier (within 4 days) was 46 and that of the control group was 8. The 
number of patients with delayed start of oral feeds was 4 in the study group and 
42 in the control group. This is statistically significant as the p value is <0.001. 
 
                   
Table 9: 
  Length of hospital stay   Cases   Controls  
  <10  48  15 
  >10  2  35 
  Total  50  50 
  P VALUE  0.002    Sig 
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About 48 out of 50 patients in the study group were discharged within 10 days 
and 15 out of 50 patients in the control group were discharged within 10 days. 2 
out of 50 patients in the study group got discharged after 10 days while 35 out 
of 50 patients got discharged only after 10 days in the control group. 
 
 
                   
Table 10: 
  Anastamotic leakage   Cases   Controls  
  Yes  0  2(4%) 
  No  50  48 
  Total  50  50 
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There were no cases of anastamotic leak in the patients in the study group. 
About 2 out of 50 patients in the control group developed anastamotic leak 
which inturn amounts to 4% of the control group. 
 
 
 
                   
Table 11: 
Abdominal wall dehiscence   Cases   Controls  
Yes  1  3 
No  49  47 
Total  50  50 
        
 
 
Chart 8: 
1 3
49 47
0
5
10
15
20
25
30
35
40
45
50
Yes No
ABDOMINAL WALL DEHISCENCE
CASES CONTROLS
 
1 out of 50 patients in the study group developed  postoperative abdominal wall 
dehiscence which amounts to 2% of the study group. While 3 out of 50 patients 
in the control group had postoperative abdominal wall  dehiscence which 
amounts to 6% of the control group. 
 
                   
Discussion : 
 
                                Postoperative ileus is an iatrogenic condition that occurs 
following abdominal surgery, characterized by a transient cessation of 
coordinated propulsive motility. The clinical manifestations include abdominal 
distention, nausea, vomiting, and inability to pass stools or tolerate a solid diet. 
Besides the discomfort experienced by patients, postoperative ileus is also an 
important risk factor for complications such as wound dehiscence and for 
pulmonary and thromboembolic complications. Current management strategies 
consist of perioperative anaesthetic and analgesic management, avoidance of 
nasogastric tube feeding and the use of supportive therapies.2 Although a variety 
of strategies have been proposed to reduce postoperative ileus, including 
feeding soon after surgery, early ambulation, epidural analgesia, fluid 
restriction, and minimally invasive surgery, none of these have been completely 
successful in preventing postoperative ileus.3 
 
                                                The etiology of postoperative ileus is 
multifactorial, but recent advances into the insight of the pathogenesis of 
postoperative ileus have identified intestinal inflammation triggered by surgical 
handling as the main mechanism. The importance of this inflammatory response 
in postoperative ileus is underscored by the beneficial effect of pharmacological 
interventions blocking the influx of leukocytes. New insights into the 
                   
pathophysiology of postoperative ileus as the involvement of the innate- and the 
adaptive (T-helper type 1 cell-mediated immune response) immune system offer 
interesting and important new approaches to prevent postoperative ileus. 
 
Limitations of the study are: 
- Diagnosis of the patients are varied and so to get a clear picture of the 
effect of gum chewing on bowel function in a specific condition , 
individual studies based on specific diagnosis have to be done. 
-  Procedure done for the same diagnosis also varies between some patients 
and hence more studies involving more patients undergoing the same 
procedure has to be done. 
- Another drawback is that the exact duration of chewing the gum could 
not be standardized, although patients were advised to chew 9 pieces per 
day divided into three sessions morning, noon and night. 
- Other confounding factors like antibiotics, transfusions and  the amount 
of  intravenous fluids given are not taken into account. 
- Age and sex based comparison is needed for more accurate conclusions. 
- Large number of patients are needed for comparing major factors like 
anastamotic leak and abdominal wall dehiscence. 
 
 
 
                   
 
CONCLUSION: 
- There was early return of bowel sounds in the postoperative period  in the 
study group compared to control group. 
- Post operative day of first passage of flatus was earlier in the study group 
- Post operative day of first passage of faeces was earlier in the study group 
- Time taken to start the oral feeds in the postoperative period was earlier 
in the study group 
- Rates of anastamotic leak and abdominal wall dehiscence could not be 
compared in this study. 
- Duration of hospital stay is lesser in the study group. 
 
                      This study clearly shows that chewing the chewing gum in 
the postoperative period aids in the early return of bowel function 
postoperatively in patients undergoing laparotomy. 
 
                   
BIBLIOGRAPHY 
1. Bennett-Guerrero E, Welsby I, Dunn TJ, et al. The use of a postoperative morbidity survey 
to evaluate patients with prolonged hospitalization after routine, moderate-risk, elective 
surgery. Anesth Analg 1999;89:514-9. 
2. Grocott MP, Browne JP, Van der Meulen J, et al. The Postoperative Morbidity Survey was 
validated and used to describe morbidity after major surgery. J Clin Epidemiol 2007;60:919 
28. 
3. Iyer S, Saunders WB, Stemkowski S. Economic burden of postoperative ileus associated 
with colectomy in the United States. J Manag Care Pharm 2009;15:485-94. 
4. Asgeirsson T, El-Badawi KI, Mahmood A, et al. Postoperative ileus: it costs more than you 
expect. J Am Coll Surg 2010;210:228-31. 
5. Barquist E, Bonaz B, Martinez V, et al. Neuronal pathways involved in abdominal 
surgeryinduced gastric ileus in rats. Am.J.Physiol 1996;270:R888-R894. 
6. Bonaz B. The cholinergic anti-inflammatory pathway and the gastrointestinal tract. 
Gastroenterology 2007;133:1370-1373. 
7. Bonaz B, Plourde V, Tache Y. Abdominal surgery induces Fos immunoreactivity in the rat 
brain. J.Comp Neurol. 1994;349:212-222. 
8. Boeckxstaens GE, de Jonge WJ. Neuroimmune mechanisms in postoperative ileus. Gut 
2009;58:1300-11. 
9. De Winter BY, Boeckxstaens GE, De Man JG, et al. Effect of adrenergic and nitrergic 
blockade on experimental ileus in rats. Br J Pharmacol 1997;120:464-8. 
10. Story SK, Chamberlain RS. A comprehensive review of evidence-based strategies to 
prevent and treat postoperative ileus. Dig Surg 2009;26:265-75. 
11. Kalff JC, Carlos TM, Schraut WH, et al. Surgically induced leukocytic infiltrates within 
the rat intestinal muscularis mediate postoperative ileus. Gastroenterology 1999;117:378-87. 
                   
12. Engel DR, Koscielny A, Wehner S, et al. T helper type 1 memory cells disseminate 
postoperative ileus over the entire intestinal tract. Nat Med 2010;16:1407-13. 
13. Kalff JC, Turler A, Schwarz NT, et al. Intra-abdominal activation of a local inflammatory 
response within the human muscularis externa during laparotomy. Ann Surg 2003;237:301-
15. 
14. The FO, Bennink RJ, Ankum WM, et al. Intestinal handling-induced mast cell activation 
and inflammation in human postoperative ileus. Gut 2008;57:33-40. 
15. Bauer AJ. Two immune arms to stop one gut. Nat Med 2010;16:1378-9. 
16. Prasad M, Matthews JB. Deflating postoperative ileus. Gastroenterology 1999;117:489-
92. 
17. de Jonge WJ, van Den Wijngaard RM, The FO, et al. Postoperative ileus is maintained by 
intestinal immune infiltrates that activate inhibitory neural pathways in mice. 
Gastroenterology 2003;125:1137-1147. 
18. de Jonge WJ, The FO, van der Coelen D, et al. Mast cell degranulation during abdominal 
surgery initiates postoperative ileus in mice. Gastroenterology 2004;127:535-545. 
19. Kreiss C, Birder LA, Kiss S, et al. COX-2 dependent inflammation increases spinal Fos 
expression during rodent postoperative ileus. Gut 2003;52:527-534. 
20. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the 
systemic inflammatory response to endotoxin. Nature 2000;405:458-462. 
21. Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha7 subunit is an 
essential regulator of inflammation. Nature 2003;421:384-388. 
22. Tracey KJ. The inflammatory reflex. Nature 2002;420:853-859. 
23. de Jonge WJ, van der Zanden EP, The FO, et al. Stimulation of the vagus nerve attenuates 
macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat Immunol 
2005;6:844-51. 
                   
24. The F, Cailotto C, van der Vliet J, et al. Central activation of the cholinergic anti-
inflammatory pathway reduces surgical inflammation in experimental post-operative ileus. Br 
J Pharmacol 2011;163:1007-16. 
25. Pavlov VA, Ochani M, Gallowitsch-Puerta M, et al. Central muscarinic cholinergic 
regulation of the systemic inflammatory response during endotoxemia. 
Proc.Natl.Acad.Sci.U.S.A 2006;103:5219- 5223. 
26. Venkova K, Fraser G, Hoveyda HR, et al. Prokinetic effects of a new ghrelin receptor 
agonist TZP-101 in a rat model of postoperative ileus. Dig Dis Sci 2007;52:2241-8. 
27. Pavlov VA, Parrish WR, Rosas-Ballina M, et al. Brain acetylcholinesterase activity 
controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Brain 
Behav Immun 2009;23:41-5. 
28. Luyer MD, Greve JW, Hadfoune M, et al. Nutritional stimulation of cholecystokinin 
receptors inhibits inflammation via the vagus nerve. J Exp Med 2005;202:1023-9. 
29. Lubbers T, Luyer MD, de Haan JJ, et al. Lipid-rich enteral nutrition reduces postoperative 
ileus in rats via activation of cholecystokinin-receptors. Ann Surg 2009;249:481-7. 
30. Zhang B, Cao A, Zhou J, et al. Effect of jatrorrhizine on delayed gastrointestinal transit in 
rat postoperative ileus. J Pharm Pharmacol 2012;64:413-9. 
31. Cailotto C, Costes LM, van der Vliet J, et al. Neuroanatomical evidence demonstrating 
the existence of the vagal anti-inflammatory reflex in the intestine. Neurogastroenterol Motil 
2011. 
32. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human 
immunology. J Immunol 2004;172:2731-8. 
33. van Bree SHWea. Which clinical symptoms reflect postoperative recovery of 
gastrointestinal motility? GUT OP257; 60 (Suppl 3) Abstract 59. Presented at: 19th United 
European Gastroenterology Week; Stockholm, Sweden, October 22-26 2011. 
                   
34. Kehlet H. Postoperative ileus--an update on preventive techniques. Nat Clin Pract 
Gastroenterol Hepatol 2008;5:552-8. 
35. Kehlet H. Fast-track surgery-an update on physiological care principles to enhance 
recovery. Langenbecks Arch Surg 2011;396:585-90. 
36. Kehlet H. Surgery: Fast-track colonic surgery and the 'knowing-doing' gap. Nat Rev 
Gastroenterol Hepatol 2011;8:539-40. 
37. Lassen K, Soop M, Nygren J, et al. Consensus review of optimal perioperative care in 
colorectal surgery: Enhanced Recovery After Surgery (ERAS) Group recommendations. 
Arch Surg 2009;144:961- 9. 
38. Basse L, Madsen JL, Billesbolle P, et al. Gastrointestinal transit after laparoscopic versus 
open colonic resection. Surg Endosc 2003;17:1919-22. 
39. Delaney CP, Marcello PW, Sonoda T, et al. Gastrointestinal recovery after laparoscopic 
colectomy: results of a prospective, observational, multicenter study. Surg Endosc 
2010;24:653-61. 
40. L acy AM, Garcia-Valdecasas JC, Delgado S, et al. Laparoscopy-assisted colectomy 
versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. 
Lancet 2002;359:2224-9. 
41. Milsom JW, Bohm B, Hammerhofer KA, et al. A prospective, randomized trial 
comparing laparoscopic versus conventional techniques in colorectal cancer surgery: a 
preliminary report. J Am Coll Surg 1998;187:46-54; discussion 54-5. 
42. Schwenk W, Bohm B, Haase O, et al. Laparoscopic versus conventional colorectal 
resection: a prospective randomised study of postoperative ileus and early postoperative 
feeding. Langenbecks Arch Surg 1998;383:49-55. 
43. Veldkamp R, Kuhry E, Hop WC, et al. Laparoscopic surgery versus open surgery for 
colon cancer: short-term outcomes of a randomised trial. Lancet Oncol 2005;6:477-84. 
                   
44. Ohtani H, Tamamori Y, Arimoto Y, et al. A meta-analysis of the short- and long-term 
results of randomized controlled trials that compared laparoscopy-assisted and open 
colectomy for colon cancer. J Cancer 2012;3:49-57. 
45. Augestad KM. Postoperative ileus: Impact of pharmacological treatment, laparoscopic 
surgery and enhanced recovery pathways. World Journal of Gastroenterology 2010;16:2067. 
46. Delaney CP, Chang E, Senagore AJ, et al. Clinical outcomes and resource utilization 
associated with laparoscopic and open colectomy using a large national database. Ann Surg 
2008;247:819-24. 
47. Tsai HL, Chen MJ, Yeh YS, et al. Comparison of Mini Laparotomy with Conventional 
Laparotomy as the Surgical Approach in Stage I-III Colorectal Cancer Patients: Appealing 
Outcomes. Hepatogastroenterology 2012;59. 
48. Traut U, Brugger L, Kunz R, et al. Systemic prokinetic pharmacologic treatment for 
postoperative adynamic ileus following abdominal surgery in adults. Cochrane Database Syst 
Rev 2008:CD004930. 
49. Camilleri M, Bharucha AE, Farrugia G. Epidemiology, mechanisms, and management of 
diabetic gastroparesis. Clin Gastroenterol Hepatol 2011;9:5-12; quiz e7. 
50. Chan DC, Liu YC, Chen CJ, et al. Preventing prolonged post-operative ileus in gastric 
cancer patients undergoing gastrectomy and intra-peritoneal chemotherapy. World J 
Gastroenterol 2005;11:4776-81. 
51. Seta ML, Kale-Pradhan PB. Efficacy of metoclopramide in postoperative ileus after 
exploratory laparotomy. Pharmacotherapy 2001;21:1181-6. 
52. Senagore AJ. Pathogenesis and clinical and economic consequences of postoperative 
ileus. Clin Exp Gastroenterol 2010;3:87-9. 
53. Becker G, Blum HE. Novel opioid antagonists for opioid-induced bowel dysfunction and 
postoperative ileus. Lancet 2009;373:1198-206. 
                   
54. Wolff BG, Michelassi F, Gerkin TM, et al. Alvimopan, a novel, peripherally acting mu 
opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, 
phase III trial of major abdominal surgery and postoperative ileus. Ann Surg 2004;240:728-
34; discussion 734-5. 
55. Ludwig K, Enker WE, Delaney CP, et al. Gastrointestinal tract recovery in patients 
undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a 
standardized accelerated postoperative care pathway. Arch Surg 2008;143:1098-105. 
56. Delaney CP, Weese JL, Hyman NH, et al. Phase III trial of alvimopan, a novel, 
peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal 
surgery. Dis Colon Rectum 2005;48:1114-25. 
57. Viscusi ER, Goldstein S, Witkowski T, et al. Alvimopan, a peripherally acting mu-opioid 
receptor antagonist, compared with placebo in postoperative ileus after major abdominal 
surgery: results of a randomized, double-blind, controlled study. Surg Endosc 2006;20:64-70. 
58. Ludwig K, Viscusi ER, Wolff BG, et al. Alvimopan for the management of postoperative 
ileus after bowel resection: characterization of clinical benefit by pooled responder analysis. 
World J Surg 2010;34:2185-90. 
59. Buchler MW, Seiler CM, Monson JR, et al. Clinical trial: alvimopan for the management 
of postoperative ileus after abdominal surgery: results of an international randomised, double-
blind, multicentre, placebo-controlled clinical study. Aliment Pharmacol Ther 2008. 
60. Touchette DR, Yang Y, Tiryaki F, et al. Economic analysis of alvimopan for prevention 
and management of postoperative ileus. Pharmacotherapy 2012;32:120-8. 
61. Abodeely A, Schechter S, Klipfel A, et al. Does alvimopan enhance return of bowel 
function in laparoscopic right colectomy? Am Surg 2011;77:1460-2. 
62. Viscusi E RJ, Fichera A, Gan TJ, Israel RJ. In: A double blind r, placebo-controlled trial 
of  methylnaltrexone (MNTX) for post-operative bowel dysfunction in segmental colectomy 
                   
patients. Abstract A893. Presented at: Annual Meeting of the American Society of 
Anesthesiologists; New Orleans, LA, October 22–26., ed, 2005. 
63. Viscusi ER, Gan TJ, Leslie JB, et al. Peripherally acting mu-opioid receptor antagonists 
and postoperative ileus: mechanisms of action and clinical applicability. Anesth Analg 
2009;108:1811-22. 
64. Yu CS, Chun HK, Stambler N, et al. Safety and efficacy of methylnaltrexone in 
shortening the duration of postoperative ileus following segmental colectomy: results of two 
randomized, placebocontrolled phase 3 trials. Dis Colon Rectum 2011;54:570-8. 
65. Herroeder S, Pecher S, Schonherr ME, et al. Systemic lidocaine shortens length of 
hospital stay after colorectal surgery: a double-blinded, randomized, placebo-controlled trial. 
Ann Surg 2007;246:192-200. 
66. Wallin G, Cassuto J, Hogstrom S, et al. Effects of lidocaine infusion on the sympathetic 
response to abdominal surgery. Anesth Analg 1987;66:1008-13. 
67. Wood JD. Excitation of intestinal muscle by atropine, tetrodotoxin, and xylocaine. Am J 
Physiol 1972;222:118-25. 
68. Groudine SB, Fisher HA, Kaufman RP, Jr., et al. Intravenous lidocaine speeds the return 
of  bowel function, decreases postoperative pain, and shortens hospital stay in patients 
undergoing radical retropubic prostatectomy. Anesth Analg 1998;86:235-9. 
69. Harvey KP, Adair JD, Isho M, et al. Can intravenous lidocaine decrease postsurgical ileus 
and shorten hospital stay in elective bowel surgery? A pilot study and literature review. Am J 
Surg 2009;198:231-6. 
70. Kuo CP, Jao SW, Chen KM, et al. Comparison of the effects of thoracic epidural 
analgesia and i.v. infusion with lidocaine on cytokine response, postoperative pain and bowel 
function in patients  undergoing colonic surgery. Br J Anaesth 2006;97:640-6. 
 
                   
                                                                   PROFORMA 
 
Name   :     I.P. No  : 
Age  :     Unit  : 
Sex  :     D.O.A  : 
Occupation  :     D.O.Surgery : 
Address :  
Phone No :     D.O.D                : 
 
CHIEF COMPLAINTS:- 
1) Abdominal pain           :  
2) Abdominal distension : 
3) Vomitting  : 
4) Constipation/diarrhoea: 
5) fever                    : 
6) melena/haematemesis   : 
7) loss of weight/appetite  : 
8) hematochezia              : 
9) dysuria/hematuria : 
 
PAST HISTORY:- 
1) History of similar complaints 
2) Treatment taken 
3) History of chronic Drug intake –opioids, anticholinergics 
                   
4) History suggestive of Hypertension / Diabetes / Tuberculosis / heart disease / jaundice / 
thyroid disorder/epilepsy 
5) History of previous surgeries in the past 
 
PERSONAL HISTORY:- 
Diet : Vegetarian / Mixed 
Habits : Smoking / Alcohol / Tobacco 
Bowel habits 
Bladder 
Sleep 
 
MENSTRUAL HISTORY:- 
 Regular / Not 
 Duration  
 Associated / Not with pain 
 L.M.P. 
             L.C.B. 
GENERAL PHYSICAL EXAMINATION : - 
1. General surey  
2. Body build and nourishment 
3. Appearance  
4. Attitude : Restless / Quiet 
5. Dehydration : Mild/ Moderate / Severe / Nil 
6. Anaemia / Jaundice / Clubbing Cyanosis / Lymphadenopathy / Pedal oedema. 
7. Eye signs  
8. Skin Changes 
9. Pulse 
                   
10. Temperature 
11. Respiratory rate 
12. Blood pressure 
 
SYSTEMIC EXAMINATION  
 Cardiovascular system 
 Respiratory System  
 Central nervous system 
 Genito - urinary system 
 Abdomen:  
Inspection : scaphoid/distended 
                     All quadrants moving equally with respiration 
                     Umbilicus position 
                     Dilated veins/scars/sinuses 
                     VGP/VIP 
Palpation: tenderness/guarding/rigidity 
                   Organomegaly/palpable mass 
Percussion : free fluid/obliteration of liver dullness 
Auscultation: bowel sounds 
P/R: sphincter tone/ palpable mass 
         Fecal staining/  per rectal bleeding 
P/V: cervical os/ presence of mass/ bleeding/discharge 
          
 
 
INVESTIGATIONS:- 
1. Blood : Hb% 
2. TLC 
3. DLC 
4. BT 
5. CT 
6. ESR 
7. Blood group and rh type. 
8. Urine : Albumin / Sugar / Microscopy 
                   
9. Blood : sugar / Urea / creatinine 
10. Serum electrolytes 
11. ECG 
12. X-ray chest PA view/ X ray abdomen erect 
13. USG abdomen and pelvis  
14. CT abdomen and pelvis 
15. Endoscopic findings 
16. HIV 
17. HbsAg 
18. Others 
 
DIAGNOSIS 
 
MANAGEMENT 
SURGICAL 
Pre operative instructions 
Type of Anaesthesia 
Intra operative findings 
Procedure  
Post - operative instructions: All the patients in the study group were allowed to chew gum from 
6 hours post surgery. 
Post operative investigations 
Post - operative period: Day of return of bowel sounds 
                                         Day of first passage of flatus 
                                         Day of start of oral feeds 
                                         Day of first passage of faeces  
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1 alagar  56 m  12231 Duodenal ulcer 
perforation 
Omental patch closure  2 2 3 3 ‐  no  7
2 malayalam  43 m  13289 Duodenal ulcer 
perforation 
Omental patch closure  3 2 3 3 ‐  no  7
3 annamalai  54 m  21787 Appendicualr 
perforation 
Exploratory laparotomy 
and appendicectomy 
2 2 3 2 ‐  no  6
4 rudhrammal  65 f  34566 Carcinoma stomach  Exploratory laparotomy 
and gastrojejunostomy 
3 3 4 4 no  no  8
5 annamal  38 f  56456 Chronic DU with GOO  Truncal vagotomy and 
gastrojejunostomy 
5 4 6 6 no  no  10
6 paramasivam  65 m  76555 Gastric perforation  Primary closure with 
biopsy 
3 3 4 3 ‐  no  7
7 rajendran  54 m  56998 Obstructed incisional 
hernia 
Exploratory laparotomy 
with resection 
anastamosis of ileum 
6 6 8 7 no  no  11
8 siva  28 m  2319 Stab injury abdomen  Primary closure of 
gastric and jejunal 
perforation
3 3 6 4 no  no  8
9 nallama  47 f  34121 Duodenal ulcer 
perforation 
Omental patch closure  3 3 5 4 ‐  no  7
10 veeran  67 m  67660 Acute intestinal 
obstruction 
Adhesion band relaease 
and peritoneal lavage 
4 4 6 4 ‐  no  8
11 periasamy  34 m  54779 Duodenal ulcer 
perforation 
Omental patch closure  2 2 4 3 ‐  no  7
12 muthu  48 m  35669 Ruptured liver abscess  Exploratory laparotomy 
and drainage 
3 3 5 4 ‐  no  8
Group 1  (CASES)
13 vasantha  50 f  43356 Gastric perforation  Primary closure and 
biopsy 
5 5 7 6 ‐  no  9
14 jaya  29 f  43299 Appendicular 
perforation 
Exploratory laparotomy 
and appendicectomy 
2 2 4 2 ‐  no  6
15 silambayee  52 f  66756 Acute intestinal 
obstruction 
Hartmanns procedure  3 3 5 5 ‐  no  9
16 balaji  18 m  11398 Stab injury abdomen  Exploratory laparotomy 
with resection 
anastamosi of ileum 
4 4 6 6 no  yes  15
17 Abdulla  34 m  21879 Carcinoma colon  Left hemicolectomy 
with end to end colon 
anastamosis
3 3 4 5 no  no  9
18 marutham  54 m  43199 Dudenal ulcer 
perforation 
Omenatal  patch closure  2 2 4 3 ‐  no  7
19 krishnan  60 m  39118 Ileal perforation  Resection anastamosis 
of terminal ileum 
3 3 5 4 no  no  8
20 arockiam  43 m  40766 Duodenal perforation  Omental patch closure  2 2 4 3 ‐  no  7
21 Babu   34 m  56646 Gastric perforation  Primary closure with 
biopsy 
2 2 3 4 ‐  no  8
22 chinthamani  54 f  6116 Blunt injury abdomen‐
liver laceration 
Exploratory laparotomy 
with gel foam 
hemostasis
2 2 4 3 ‐  no  7
23 jayanthi  40 f  1126 Stab injury abdomen  Exploratory laparotomy 
with primary closure of 
jejunal perforation 
2 2 4 3 no  no  8
24 natarajan  39 m  23289 Acute intesinal 
obstruction 
Adhesive band release 
with resection 
anastamosis of ileum
2 3 5 4 no  no  8
25 ponnusamy  45 m  56880 Carcinoma stomach  Subtotal gastrectomy 
with gastrojejunostomy 
3 4 6 4 no  no  9
26 muthaiah  50 m  43313 Biliary peritonitis  Laparotomy and 
peritoneal lavage 
3 3 5 4 ‐  no  8
27 valarmathi  34 f  56640 Duodenal ulcer 
perforation 
Omental patch closure  2 2 4 3 ‐  no  7
28 chandran  66 m  41339 Appendicular mass 
with caecal perforation 
Limited resection with 
ileocolic  anastamosis 
4 3 5 4 no  no  9
29 raja  55 m  54997 Gastric perforation  Primary closure with 
biopsy 
2 2 4 3 ‐  no  6
30 muthukrishnan  70 m  77456 Acute intestinal 
obstruction 
Resection anastamosis 
of ileum 
3 2 5 4 no  no  8
31 rameswari  43 f  34459 Blunt injury abdomen  Primary closure of 
jejunal perforation 
3 2 4 4 ‐  no  7
32 nagammal  45 f  11177 Obstructed incisional 
hernia 
Resection anastamosis 
of jejunum 
3 2 5 4 no  no  7
33 prashanth  19 m  22665 Hemoperitoneum‐
umbilical vein rupture 
Laparotomy with 
umbilical vein ligation  
2 2 4 3 ‐  no  7
34 Vasantha   54 f  44522 Post resectionn 
ileostomy 
Ileostomy take down  3 2 5 4 no  no  8
35 pandi  45 m  54226 Ruptured liver abscess  Laparotomy and 
drainage 
2 2 4 2 ‐  no  6
36 ganesan  50 m  1108 Stab injury abdomen  Laparotomy and closur 
of jejunal 
perforation,peritoneal 
lavage
3 2 4 3 ‐  no  7
37 ayyamal  50 f  34467 Acute intestinal 
obstruction 
Laparotomy with 
resection of gangrenous 
ileum and ileostomy 
3 2 5 4 ‐  no  8
38 peerumal  48 f  45598 Carcinoma stomach  Laparotomy and 
gastrojejunostomy 
3 2 4 4 no  no  7
39 sevagan  44 m  54438 Duodenal ulcer 
perforation 
Omental patch closure  2 2 4 3 ‐  no  7
40 lakshmi  54 f  11669 Obstructed incisional 
hernia 
Laparotomy and 
resection of ileum with 
ileostomy
3 3 4 4 ‐  no  8
41 karuppan  45 m  22567 Appendicular 
perforation 
Adhesive band release 
with appendicectomy 
3 2 5 3 ‐  no  6
42 kumar  38 m  11176 Acute intestinal 
obstruction 
Release of malrotation 
with resection 
anastamosis of ileum 
3 3 5 4 no  no  8
43 Krishana  48 m  44908 Carcinoma stomach  Subtotal gastrectomy 
with gastrojejunostomy 
3 2 5 4 no  no  8
44 ellamal  67 f  31900 Chronic duodenal ulcer 
with GOO 
Truncal vagotomy with 
gastrojejunostomy 
3 2 4 4 no  no  7
45 elumalai  55 m  37756 Duodenal ulcer 
perforation 
Omental patch closure  2 2 4 3 ‐  no  7
46 shanmugam  34 m  42230 Duodenal ulcer 
perforation 
Omental patch closure  2 2 4 3 ‐  no  7
47 velmurugan  56 m  54430 Appendicular 
perforation 
Laparotomy with 
appendicectomy 
2 2 4 2 ‐  no  6
48 ramar  56 m  43760 Duodenal ulcer 
perforation 
omental patch closure  4 3 6 5 no  no  10
49 balaji  19 M   3390 Blunt injury abdomen  Laparotomy with open 
suprapubic 
catheterisation
3 2 3 3 ‐  no  8
50 murugan  45 m  33679 Right iliopsoas abscess  Laparotomy with 
drainage 
2 2 4 3 ‐  no  7
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51 chandrakumar  52 m  44141 Gastric 
perforation 
Primary closure 
with biopsy 
5 4 6 6 ‐  no  10
52 karuppaiah  45 m  56417 Duodenal ulcer 
perforation 
Omental patch 
closure 
4 6 7 6 ‐  no  11
53 karthikeyan  57 m  32556 Intestinal 
obstruction with 
ileal perforation 
Resection 
anastamosis of 
ileum 
6 7 8 7 no  no  11
54 chinnasamy  70 m  11199 Appendicular 
perforation 
Exploratory 
laparotomy with 
appendicectomy
4 5 7 6 ‐  no  9
55 chellapandi  54 m  40778 Carcinoma 
stomach 
Subtotal 
gastrectomy with 
gastrojejunostomy 
5 6 9 7 no  no  12
56 gandhi  60 m  32997 Carcinoma 
stomach 
Gastrectomy with 
gastrojejunostomy 
6 7 9 7 no  no  13
57 aadhimoolam  48 m  43398 Perforative 
peritonitis 
Primary closure of 
ileal perforation 
5 6 9 6 ‐  no  11
58 chinnakannu  39 f  55679 Obstructed 
incisional hernia 
Exploratory 
lapartotomy and 
mesh repair
5 6 8 6 ‐  yes  17
59 mahamayee  55 f  43225 Duodenal ulcer 
perforation 
Omental patch 
closure 
5 6 9 6 ‐  no  12
60 mohan  50 m  35577 Duodenal ulcer 
perforation 
Omental patch 
closure 
5 7 9 6 ‐  no  11
61 sudalaimadan  55 m  33256 Stab injury 
abdomen 
Primarty closure 
of jejunal 
perforation
4 5 6 5 ‐  ‐  8
62 chokkar  56 m  11676 Stab injury 
abdomen 
Resection 
anastamosis of 
ileum
5 6 9 7 no  no  12
63 chokkalingam  48 m  21137 Duodenal ulcer 
perforation 
Omenatal patch 
closure 
4 5 8 6 ‐  no  11
64 nagamani  43 f  34550 Gastric 
perforation 
Primary closure 
with biopsy 
4 5 7 6 ‐  no  10
65 mahalingam  54 m  54676 Chronic 
duodenal  ulcer 
with GOO 
Truncal vagotomy 
with 
gastrojejunostomy 
5 6 10 6 no  no  13
66 ranjith  24 m  11678 Duodenal ulcer 
perforation 
Omental patch 
closure 
4 6 9 6 ‐  no  12
67 chinnatahmbi  48 m  32777 Perforative 
peritonitis 
Ileal resectiionn 
anastamosis 
6 7 9 7 yes  yes  18
68 ramkani  56 f  32997 Obstructed 
umbilical hernia 
Resection 
anasastamosis of 
jejunum
5 6 9 7 no  no  12
69 Paravathy ammal  65 f  41227 Obstructed 
umbilical hernia 
Resection 
anastamosis of 
ileum
5 7 9 7 no  no  12
70 muthuraman  45 m  34555 Duodenal ulcer 
perforation 
Omental patch 
closure 
4 5 9 6 no  no  11
71 dachanamoorthy  76 m  54336 Blunt injury 
abdomen 
Primary closure of 
ileal perforation 
6 6 10 7 no  no  11
Group 2
CONTROLS
72 moorthy  65 m  43376 Carcinoma 
stomach 
Gastrectomy with 
gastrojejunostomy 
5 6 10 6 no  no  12
73 kamatchammal  55 f  56448 Liver hydatid 
cyst 
Exploratory 
laparotomy with 
cystopericystecto
my
4 6 10 5 no  no  12
74 alagammmal  48 f  54889 Chronic DU with 
GOO 
Truncal vagotomy 
with 
gastrojejunostomy 
5 7 9 6 no  no  11
75 Chinnaponnnu  56 f  22340 Obstructed 
incisional henia 
Laparotomy and 
mesh repair 
5 6 9 6 no  no  11
76 ganesan  45 m  11887 Duodenal ulcer 
perforation 
Omental patch 
closure 
5 7 9 5 no  no  10
77 ponamala  65 f  54346 Carcinoma 
stomach 
Anterior 
gastrojejunostomy 
5 7 9 7 no  no  11
78 bhavani  28 f  32990 Appendicular 
perfortion 
Laparotomy and 
appendicectomy 
4 5 7 5 ‐  no  9
79 nallamal  55 f  66331 Acute intestinal 
obstruction 
Resection 
anastamosis of 
ileum
6 6 10 7 no  no  13
80 velamal  54 f  54399 Chronic DU with 
GOO 
Truncal vagotomy 
with 
gastrojejunostomy 
5 6 10 7 no  no  12
81 chellamal  45 f  21449 Duodenl ulcer 
perforation 
Omental patch 
closure 
4 6 9 5 ‐  no  11
82 selvarasu  67 m  45669 Duodenal ulcer 
perforation 
Omental patch 
closure 
4 5 8 6 ‐  no  10
83 kanagaraj  45 m  66544 Gastric 
perforation 
Primary closure 
and biopsy 
5 6 9 6 ‐  no  11
84 chinna  18 m  3324 Blunt injury 
abdomen 
Primary closure of 
jejunal perforation 
5 6 10 7 ‐  no  11
85 manivel  56 m  63321 Blunt injury 
abdomen 
Resection 
anastamosis of 
ileum
5 7 9 8 yes  yes  19
86 abdullah  76 m  43880 Carcinoma 
stomach 
Gastrectomy with 
gastrojejunostomy 
5 6 9 7 no  no  11
87 ramkani  66 f  64332 Carcinoma 
stomach 
Anterior 
gastrojejunostomy 
4 6 8 6 no  no  10
88 devaraj  43 m  23665 Duodenal ulcer 
perforation 
Omental patch 
closure 
5 6 9 6 ‐  no  11
89 kalanjiyam  48 m  56448 Duodenal ulcer 
perforaion 
Omental patch 
closure 
5 6 9 5 ‐  no  10
90 siva  28 m  12290 Stab injury 
abdomen 
Resection 
anastamosis of 
jejunum
5 7 8 6 no  no  10
91 maruthu  56 m  32209 Acute intestinal 
obstruction 
Hartmanns 
procedure 
5 6 7 6 ‐  no  10
92 nagamal  65 f  43008 Gastric 
perforation 
Primary closure 
with biopsy 
5 6 9 6 ‐  no  9
93 palani  49 m  39908 Chronic DU with 
GOO 
Truncal vagotomy 
withh 
gastrojejunostomy 
4 6 8 6 no  no  11
94 karuppu  57 m  65004 Duodenal ulcer 
perforation 
Omental patch 
closure 
4 6 9 6 ‐  no  10
95 visalam  67 f  43776 Duodenal ulcer 
perforation 
Omental patch 
closure 
3 5 8 5 ‐  no  9
96 vijayaranii  36 m  55448 Obstructed 
umbilical hernia 
Resection 
anastamosis of 
ileum
5 6 9 6 no  no  11
97 ilango  56 m  23300 Perforative 
peritonitis 
Resection 
anastoamosis of 
ileum
4 6 9 6 no  no  11
98 suresh  48 m  33767 Acute intestinal 
obstruction 
Ileal stricture 
resection with 
ileostomy
5 6 7 7 ‐  no  13
99 Maniivel   56 m  55500 Acute intestinal 
obstruction 
Right 
hemicolectomy 
with 
ileotransverse 
anastamosis
5 5 9 7 no  no  12
100 palpandi  49 m  56643 Gastric 
perforation 
Primary closure 
with biopsy 
4 5 7 5 ‐  no  9
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